

# The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE

Rita J. Guerreiro<sup>a,b,\*</sup>, Deborah R. Gustafson<sup>c,d</sup>, John Hardy<sup>e</sup>

<sup>a</sup> *Laboratory of Neurogenetics, National Institute of Aging, National Institutes of Health, Bethesda, MD, USA*

<sup>b</sup> *Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal*

<sup>c</sup> *Neuropsychiatric Epidemiology Unit, Sahlgrenska Academy, University of Gothenburg, Sweden*

<sup>d</sup> *Departments of Neurology and Medicine, SUNY-Downstate Medical Center, Brooklyn, NY, USA*

<sup>e</sup> *Reta Lila Weston Institute and Departments of Molecular Neuroscience and Neurodegenerative Disease, Institute of Neurology, London, UK*

Received 9 September, 2009; received in revised form 1 March 2010; accepted 11 March 2010

## Abstract

Alzheimer's disease (AD) is a complex disorder with a clear genetic component. Three genes have been identified as the cause of early onset familial AD (EOAD). The most common form of the disease, late onset Alzheimer's disease (LOAD), is, however, a sporadic one presenting itself in later stages of life. The genetic component of this late onset form of AD has been the target of a large number of studies, because only one genetic risk factor (APOE4) has been consistently associated with the disease. However, technological advances allow new approaches in the study of complex disorders. In this review, we discuss the new results produced by genome wide association studies, in light of the current knowledge of the complexity of AD genetics.

Published by Elsevier Inc.

## 1. Introduction

Historically, Alzheimer's disease (AD) is the most common cause of dementia. It is a progressive neurodegenerative disorder with an insidious onset, which typically appears in older individuals, but may affect people as early as the third decade of life (Rademakers et al., 2003; Rogaeva, 2002). The genetics of Alzheimer's disease is complex and heterogeneous. Most cases are "sporadic" with no apparent familial recurrence of the disease. However, a small percentage of AD cases (1–2% of all cases) have an early onset (EOAD), with symptoms appearing before 65 years of age. In these patients, the disease commonly aggregates within families and typically presents an autosomal dominant pattern of inheritance. Mutations in three genes are known to account for this early onset, familial type of the disease: amyloid precursor protein gene (*APP*), presenilin 1 gene (*PSEN1*) and presenilin 2 gene (*PSEN2*) (Rogaeva, 2002).

In fact, early-onset autosomal dominant disease with age of onset younger than 60 years, seems to be completely explained by pathogenic mutations in these three genes.

The most common, late onset and sporadic form of the disease remains mostly a genetic conundrum. The only well-established genetic risk factor for late onset AD (LOAD) is the E4 allele of apolipoprotein E although many lifestyle risk factors have been reported including low education, midlife high blood pressure and cholesterol levels, obesity, and diabetes (Rogaeva, 2002). It has been estimated that the four established AD genes account for less than 30% of the genetic variance in EOAD and LOAD, suggesting that numerous additional AD genes may exist (Daw et al., 2000). The pursuit of these additional genes has been unproductive until recently. In the last 2 years, however, high throughput technologies able to genotype up to one million single nucleotide polymorphisms (SNPs) have revealed some of the genetic players in different complex disorders. In this review, we will consolidate the current knowledge on the role of *APP*, PSENs, and APOE in AD, we will systematically review the most promising new loci

\* Corresponding author at. Tel.: 301 435 8866; fax: 301 451 7295.  
E-mail address: portalegrer@nia.nih.gov (R.J. Guerreiro).

and variants reported to be associated with AD, and we will discuss the recent advances in AD genome wide analysis in the context of the known epidemiology of the disorder.

### 1.1. Early onset Alzheimer's disease causative genes (*APP*, *PSEN1*, and *PSEN2*)

The amyloid precursor protein gene (*APP*, OMIM 104,760, chromosome 21q21) encodes a ubiquitously expressed, integral Type I membrane glycoprotein that exists as different alternatively spliced isoforms, with three predominant ones: APP751, APP770, and APP695, the latter being the main isoform found in the brain (Yoshikai et al., 1990). The proteolytic processing of *APP* results in the production of different peptides (including A $\beta$ ), after a series of secretase cleavages, and occurs through two mutually exclusive pathways: the amyloidogenic pathway (fundamentally considered as the pathogenic pathway) and the non-amyloidogenic or constitutive pathway (Esch et al., 1990; Haass et al., 1992; Shoji et al., 1992). The identification of A $\beta$  as a metabolic product of *APP* and the reports of AD families harboring *APP* causative mutations led to the general concept that A $\beta$  is a key player in the development of AD, and that EOAD mutations are influencing the properties or ratios of the different A $\beta$  isoforms in the brain (Hardy, 1997). Dominant mutations in *APP* are, however, a rare cause of AD with an estimated frequency of 16% of familial EOAD patients (Raux et al., 2005). More recently, two mutations in *APP* (A673V and E693 $\Delta$ ) have been reported to cause AD only in the homozygous state in families with apparently recessive modes of inheritance (Di Fede et al., 2009; Tomiyama et al., 2008).

In addition to missense variants, copy number mutations have been identified in autosomal dominant early-onset families. Five French families (Cabrejo et al., 2006; Rovelet-Lecrux et al., 2006) were first reported to harbor small chromosomal duplications with different break points, but all including the *APP* locus. Subsequent screens in Finnish and Dutch AD cases revealed additional *APP* duplications in EOAD cases with prominent cerebral amyloid angiopathy (CAA) (Remes et al., 2004; Rovelet-Lecrux et al., 2007; Sleegers et al., 2006). The phenotypic spectrum of *APP* duplications is yet to be fully defined but clearly includes mixed phenotypes of AD and/or CAA. The estimated frequency of duplications also appears to be variable: in the selected Rovelet-Lecrux cohort it was 8% (about half the contribution of missense *APP* mutations to early onset, autosomal dominant AD) (Raux et al., 2005); in the Dutch cohort less than 2% (Sleegers et al., 2006); in EOAD familial and sporadic Swedish and Finnish cases there were no duplications in *APP* identified (Blom et al., 2008); and a frequency of 18% was estimated in early onset familial Japanese cases (Kasuga et al., 2009).

The presenilin 1 (*PSEN1*, OMIM 104,311, chromosome 14q24.3) and presenilin 2 (*PSEN2*, OMIM 600,759, chromosome 1q31-q42) genes have a very similar genetic struc-

ture and encode two proteins expressed in a multiplicity of tissues including the brain, with higher levels in the cerebellum and the hippocampus and a primarily neuronal expression (Levy-Lahad et al., 1996; Rogaev et al., 1995). These are highly homologous, sharing an overall amino acid sequence identity of 67%. Hydrophobicity plots predicted these to be integral membrane proteins (Rogaev et al., 1995) most likely adopting a transmembrane structure containing nine segments with a hydrophilic intracellular loop region (Henricson et al., 2005; Laudon et al., 2005). *PSEN*s are important components of the multimeric gamma-secretase complex and are predominantly located in the endoplasmic reticulum and Golgi compartments, clearly suggesting their involvement in protein processing (Kovacs et al., 1996; De Strooper, 2003). The first disease causing mutations in *PSEN1* and *PSEN2* were identified in 1995 (Rogaev et al., 1995; Sherrington et al., 1995). Today, 175 pathogenic mutations and seven variants nonpathogenic or with unclear pathogenicity have been identified in *PSEN1*. *PSEN2* harbors fewer mutations: 14 pathogenic mutations and nine variants nonpathogenic or with unclear pathogenicity ([www.molgen.ua.ac.be/ADMutations](http://www.molgen.ua.ac.be/ADMutations), accessed in August 2009). The *PSEN*s mutation range encompasses mainly missense mutations scattered all over the proteins, with some clustering around transmembrane domains (Guerreiro et al., 2010; Hardy and Crook, 2001).

### 1.2. Genetic risk for Alzheimer's disease (*APOE*)

The apolipoprotein E gene (*APOE*, OMIM 107,741, chromosome 19q13.2) encodes a glycoprotein synthesized mainly in the liver, brain (primarily by neurons and astrocytes), and also by other cells such as macrophages and monocytes (Siest et al., 1995). *APOE* is involved in the mobilization and redistribution of cholesterol in the periphery and also during neuronal growth and repair (Mahley, 1988); in nerve regeneration, immunoregulation and activation of several lipolytic enzymes (Mahley and Rall, 2000). The three major *APOE* isoforms (ApoEII, ApoEIII and ApoEIV) differ in two sites of the amino acid sequence (residues 112 and 158) and are encoded by a single genetic locus. The frequencies of the  $\epsilon$ 2,  $\epsilon$ 3, and  $\epsilon$ 4 alleles were estimated at 0.11, 0.72, and 0.17, respectively, but vary widely among populations (Zannis et al., 1981). The  $\epsilon$ 4 allele, (the ancestral allele), is more frequent in populations such as Pygmies (0.407) and Khoi San (0.370). The  $\epsilon$ 2 allele frequency oscillates with no apparent trend and, for example, is absent in some Native Americans populations (Corbo and Scacchi, 1999).

Many studies have demonstrated an association between the  $\epsilon$ 4 allele and familial and sporadic forms of LOAD. This allele represents an increased risk seen across different ethnic groups of 3-fold for heterozygous carriers and up to 15-fold for individuals who are  $\epsilon$ 4 homozygotes, when compared with  $\epsilon$ 3 homozygotes (Ashford, 2004). *APOE* is known to act in a dose dependent manner in AD: the effect

of the  $\epsilon 4$  allele in the risk for AD increases from 20% to 90% and the mean age of onset decreases from 84 to 68 years with the increase in the number of  $\epsilon 4$  alleles (Corder et al., 1993). The  $\epsilon 2$  allele has been shown to have an impact on longevity and may confer protection against AD (Corder et al., 1994). Distinct binding properties of the different APOE isoforms to the A $\beta$  peptide (Strittmatter et al., 1993) and tau protein (Strittmatter et al., 1994) have been suggested to underlie the disparities associated with each genotype. In particular, the ApoEIV isoform binds to the A $\beta$  peptide more rapidly than the ApoEIII isoform, forming novel monofibrils that precipitate into dense structures (Sanan et al., 1994). The fact that ApoEIV does not bind to tau protein *in vitro*, unlike ApoEII and ApoEIII, has suggested to some that this interaction between ApoEIII and tau serves as a protection against tau phosphorylation and consequent neurofibrillary tangle formation (Strittmatter et al., 1994; Weisgraber, 1994).

The  $\epsilon 4$  allele appears to be a risk factor and not an invariant cause of AD, indicating that other environmental or genetic factors may need to be concurrently acting with this allele to cause AD (Hyman et al., 1996). For example, physical activity has been shown to be protective for dementia in non-APOE $\epsilon 4$  carriers (Podewils et al., 2005). Additionally, while most of the risk at the APOE locus is likely to be encoded at the protein coding polymorphism, it is likely that other genetic variability at this locus, probably altering APOE expression, also contributes to the risk of developing AD (Bekris et al., 2009; Chartier-Harlin et al., 1994; Lambert et al., 1997; Lambert et al., 2002). Genetic variability in APOE expression may contribute more to disease risk, rather than independent effects of the adjacent gene *TOMM40*.

During the past two decades there have been many studies searching for genetic risk factors: hundreds of positive and negative results have been produced, but none apart from APOE have produced clear and reproducible associations.

## 2. Different types of studies in AD genetics

Methodologically, two main genetic strategies have governed the field: genetic linkage analysis and case-control association studies. For linkage analysis, researchers have used informative families where a clear heritability of the disease is present and no mutations have been found. In association studies, researchers compare the frequencies of a predetermined allele between a group of AD cases and a group of healthy individuals. Several considerations are relevant for both strategies, of which we will mention the main ones. A full discussion of all methodological issues involved in these types of studies goes beyond the scope of this review. Here we will briefly describe the known genes and risk factors associated with AD, with a focus on genome wide association studies (GWAS) as a methodology for

exploring genetic susceptibility and identifying risk factors and mechanisms for disease. We will also address the previously overlooked role of homozygosity and recessive cases in the major complexity of AD genetics.

### 2.1. Linkage studies

Genetic linkage studies aim to identify chromosomal regions associated with disease by measuring the correlated segregation of particular markers with a determined phenotype within a family (Teare and Barrett, 2005). This type of study usually involves three sequential steps: 1) the identification of the disease causative locus; 2) sequencing the region found in the previous step in a cohort of cases and controls to define and characterize the mutation(s) found; 3) uncovering the molecular and biological functions of the genes found (Altshuler et al., 2008). Several factors are known to complicate this approach in AD: i) difficulties in getting large, complete and informative multigeneration families; ii) the potential inclusion of phenocopies (individuals with a sporadic indistinguishable form of disease); and iii) genetic heterogeneity, since observing that the pattern of disease in families is consistent with a major gene component does not necessarily imply that only one gene or factor is involved. Additionally, linkage mapping suffers from limitations, such as the low resolution of the results. Usually these studies do not identify one gene or one mutation associated with a disease, but rather a chromosomal region (many times, a very large region) is identified. In addition, the strongest linkage signals tend to come from recessive and highly penetrant, thus very rare, disorders (Teare and Barrett, 2005).

Nonetheless, linkage mapping has been a very important methodology in the study of AD genetics. The four genes undoubtedly associated with AD were identified primarily by linkage analysis. In addition to these genes, several other genomic regions have been implicated using this methodology (Table 1). These loci contain many genes that have been considered candidates and consequently have been studied to identify the genetic variation responsible for the development of AD. Until now, no specific genes implicated in AD have been identified in these regions. Most recently, a study by Butler and colleagues used a meta-analysis method to analyze the pooled linkage results from five independent genome scans. These included the results of 2,206 affected individuals and 785 families of Caucasian and Caribbean Hispanic descent. This study was able to identify genome-wide suggestive evidence for linkage on chromosomes 1p13.3-q31.1, 7pter-p21.1 and 8p22-p21.1, together with other seven loci presenting nominally significant evidence for linkage (Butler et al., 2009). Interestingly, the most significant locus identified in this study (8p22-p21.1) includes the *CLU* gene, (the top hit from the largest GWAS performed in AD, as discussed below in this review) and previously reported loci by different studies (as 9p, 9q, 10q, and 12p) were not identified by Butler and

Table 1  
Ten most interesting AD linkage regions

Chr	Region	Number of studies	Studies	LOD scores	Relevant genes
1	1p13.3-q23.3	2	(Liu et al., 2007); (Butler et al., 2009)	5.2	GSTM4; GSTM1; GSTM3; CSF1; NGF; HMGCS2; PRKAB2; APH1A; CTSS; THEM5; FAM63A; CHRN2; LMNA; PMVK; FDPS; APOA1BP; GBA; NTRK1; CRP; NCSTN
	1q23.3-q31.1	3	(Liu et al., 2007); (Butler et al., 2009); (Blacker et al., 2003)	2.1–4.0	F11R; USF1; FCER1G; RGS4; APOA2; RXRG; POU2F1; PRDX6; SOAT1; PTGS2
5	5p13-p15	6	(Pericak-Vance et al., 2000); (Curtis et al., 2001); (Olson et al., 2002); (Myers et al., 2002); (Blacker et al., 2003); (Lee et al., 2006)	1.4–2.8	SLC6A3; PRKAA1
8	8p22-p21.1	2	(Butler et al., 2009); (Lee et al., 2008)	> 2.0	NAT1; NAT2; LPL; ADRA1A; CHRNA2; CLU
9	9p21	5	(Pericak-Vance et al., 2000); (Curtis et al., 2001); (Myers et al., 2002); (Scott et al., 2003); (Hamshere et al., 2007)	> 1.0–4.6	IFT74
	9q22-q34	8	(Pericak-Vance et al., 2000); (Curtis et al., 2001); (Olson et al., 2002); (Myers et al., 2002); (Blacker et al., 2003); (Holmans et al., 2005); (Lee et al., 2006); (Hamshere et al., 2007)	1.6–4.2	FBP1; GOLM1; ABCA1; DFNB31; TLR4; NDUFA8; PSMB7; HSPA5; POMT1; DBH; RXRA; TRAF2; ABCA2
10	10q21-q22	7	(Curtis et al., 2001); (Olson et al., 2002); (Myers et al., 2002); (Blacker et al., 2003); (Holmans et al., 2005); (Liu et al., 2007); (Hamshere et al., 2007)	1.8–4.15	ZWINT; UBE2D1; TFAM; BICC1; ANK3; CDC2; EGR2; CTNNA3; LRRTM3; DNAJC12; SIRT1; SRGN; SUPV3L1; TSPAN15; VPS26A; HK1; TACR2; NEUROG3; SARA1A; SGPL1; PSAP; CHST3; PPP3CB; SEC24C; NDST2; CAMK2G; PLAU; VCL; AP3M1; MYST4; KCNMA1
12	12p11-p13	4	(Pericak-Vance et al., 1997); (Curtis et al., 2001); (Myers et al., 2002); (Holmans et al., 2005)	1.4–3.9	TNFRSF1A; CNAP1; GAPDH; GNB3; C1R; APOBEC1; MMP-3; A2M; PZP; A2MP; OLR1; LRP6; GRIN2B; GYS2; ABCC9; PKP2P1
19	19q12-q13.33	9	(Pericak-Vance et al., 2000); (Curtis et al., 2001); (Olson et al., 2002); (Myers et al., 2002); (Li et al., 2002); (Blacker et al., 2003); (Holmans et al., 2005); (Hamshere et al., 2007); (Sillen et al., 2008); (Butler et al., 2009)	1.6–7.7	LRP3; USF2; GAPDHS; PSENEN; AKT2; TGFB1; Lipe; XRCC1; Bcl-3; APOE; PVRL2; TOMM40; APOC1; APOC2; ERCC2; CARD8; GYS1; LHB; CD33; NR1H2
21	21q21-q22	4	(Olson et al., 2002); (Myers et al., 2002); (Blacker et al., 2003); (Holmans et al., 2005)	1.6–4.5	PRSS7; NCAM2; APP; C21orf63; C21orf55; RUNX1; C21orf55; DYRK1A; KCNJ6; BACE2

Note that: results by (Kehoe et al., 1999) and (Lee et al., 2004) were not considered as they were significantly extended in the same groups' follow-up genome screen (Myers et al., 2002 and Lee et al., 2006, respectively). The results by Hamshere et al. (2007) consist of an amalgamated of three datasets previously studied by Kehoe et al. (1999); Myers et al. (2002); Blacker et al. (2003) and Holmans et al. (2005). Other studies have been published that performed reanalyses of existing data either by incorporating other variables (such as evidence for AD with and without psychosis (e.g. Bacanu et al., 2002), (Avramopoulos et al., 2005), (Hollingworth et al., 2007)), or parent of origin effects, e.g. (Bassett et al., 2002). Results by (Ashley-Koch et al., 2005) and (Hahs et al., 2006) on Amish families were not considered due to the inclusion of MCI cases.

These regions were selected either from the top three regions resulting from the recent meta-analysis performed by Butler and colleagues, or from the overlapping between four or more whole-genome studies assessing linkage with AD risk, based on the AlzGene database of concordant linkage/association regions observed in full genome screens ([www.alzforum.org/res/com/gen/alzgene/linkage.asp](http://www.alzforum.org/res/com/gen/alzgene/linkage.asp)). The relevant genes for each of the represented regions were obtained from crosschecking with the AlzGene database ([www.alzgene.org](http://www.alzgene.org), (Bertram et al., 2007)).

colleagues. Even so, linkage analysis has largely failed to identify risk factors in LOAD, probably due to the low odds ratios associated with the unidentified variants.

## 2.2. Gene association studies

The quest for genetic risk factors in clinical genetics has mainly focused on the study of candidate genes (usually focusing only on variants altering the coding sequence of a gene). These types of studies rely on a rather simple principle: to test if a determined allelic or genotypic variant occurs more or less often in a group of people with a particular disease when compared with a similar group of healthy individuals.

The success of this approach relies in an in-depth under-

standing of the disease and disease pathways, in such a way that the researcher will be able to select, not only the right gene, but also the right variant(s) to be studied. Additionally, the two studied groups need to be homogeneous, well characterized and large enough to allow a statistically powerful analysis (Hattersley and McCarthy, 2005).

Most gene association studies in AD have studied a few variants in one or two genes. The large number of genes and even more variants, clearly reduce the chances of true positive findings. Nonetheless, several hundreds of positive associations have been reported. Most of these are certainly false positives resulting mainly from population substructure (i.e. existence of subpopulations in which there was random mating with reduced amount of gene flow, that may

lead to spurious associations when the geographical origin/ancestry of cases and controls are not matched) (Tian et al., 2008), poor statistical analysis and publication bias toward positive results (Choudhry et al., 2006; Ioannidis et al., 2001). Positive associations have been broadly published, while negative results (unless convincingly refuting previous results) would not be reported. When reported, most of these studies pointed to small sample sizes, or specific genetic population backgrounds as main reasons for the negative results. Other issues, particularly in large epidemiologic studies, include case definition or the ability to accurately identify AD versus vascular or other forms of dementia; age of dementia onset estimation; and phenotypic variations in the disease whether cognitive, vascular, psychiatric or metabolic.

To address these very large numbers of conflicting reports, a database (the AlzGene database) was created which systematically collects, summarizes and meta-analyzes the results for all the genetic variants studied in association with AD (Bertram et al., 2007). As of 16th November 2009 the top 10 results in this database included: *APOE* (E2/3/4), *CLU*, *PICALM*, *TNKL1*, *ACE*, *TFAM*, *CST3*, *IL1B*, *CRI* and *hCG2039140* (Bertram and Tanzi, 2008). The fifth top hit, *ACE*, has repeatedly been reported as associated with AD (Webster et al., 2009), atherosclerosis (Sayed-Tabatabaei et al., 2003) and hypertension (Staessen et al., 1997). The role of vascular risk factors in AD is further discussed below.

### 2.3. Genome wide association studies

The development of platforms able to genotype millions of SNPs and of powerful analytical frameworks, able to distinguish true associations; together with the completion of the International Human HapMap project (International Human HapMap Consortium, 2005), have provided unprecedented tools to the study of the so-called “Common Disease-Common Variant” (CD–CV) hypothesis. This theory proposes that common polymorphisms (usually defined as having a minor allele frequency of over 5%) may contribute to the overall susceptibility to common diseases (Cargill et al., 1999; Chakravarti, 1999; Lander, 1996). This type of analysis addresses one of the major pitfalls of gene association studies: the coverage of the study. Instead of studying one or two genetic variants, we are now able to test most common variability in the genome for association with disease, by means of testing tagging SNPs, i.e. polymorphisms in linkage disequilibrium (LD) with each other. This means that if one knows the genotype in one locus, one can predict with a high accuracy (dependent on the strength of the LD and the allele frequencies) the genotype occurring at linked loci. However, these platforms require the analyses of large numbers of samples and some regions of the genome are still not well covered. Thus, the success of GWAS depends on sample size, frequency of risk alleles and individual effect sizes. The smaller the attributable risk associated with any given common variant, the greater the number

of samples needed to identify that variant. The risk allele frequency relates to the effect size: a risk variant that has a high odds ratio but is rare in the population is much more difficult to identify with GWAS than a common variant linked to moderate or mild risk within the population. Additionally, population stratification (when cases and non-cases are not genetically similar); population admixture (when several distinct, unrecognized subpopulations comprise the same group of individuals studied) and unreported relatedness in the population may also be problems if the study is not correctly designed (Simon-Sanchez and Singleton, 2008).

The competing hypothesis to explain the genetic basis of complex diseases is the “Common Disease-Rare Variant” (CD–RV) theory, which suggests that multiple rare variants underlie susceptibility to such diseases (Fearnhead et al., 2005). Although the CD–CV versus CD–RV is a false dichotomy, it has major implications for the future of the research in this field, since different techniques are used to find common versus rare alleles. By definition, rare variants have low frequencies (MAF > 0.1% to 2–3%) and individually small contributions to the overall inherited susceptibility of a disease. In this way, rare variants will not be detectable by GWAS. Instead, the choice of candidate genes and appropriate case groups has been essential to uncover this type of variants (Bodmer and Bonilla, 2008). The new sequencing technologies will facilitate this approach by allowing the assessment of all the genes in the genome. Nonetheless, the extensive DNA resequencing of the whole genome in large numbers of individuals, and the assessment of the functional consequences of the variants found, poses difficult bioinformatic and data management challenges.

There is no doubt that GWAS have uncovered previously unknown polymorphic variants and genes with significant effects on AD risk. However, considering the studies so far carried out in AD (see next section for details), the associations still to be found will have ORs lower than 1.2. This has raised the question as to whether it is worthwhile to pursue even larger GWAS to identify variants with small effects disease risk. Certainly, in the future, sequencing and association strategies will be employed together to fully dissect the genetic architecture of the risk of AD and other complex disorders (Bodmer and Bonilla, 2008).

Since *APOE* has been the only risk factor consistently associated with LOAD and some reports have estimated a heritability of AD between 60% and 80% (Gatz et al., 2006; Pedersen et al., 2001) it is believed that genetic variability plays a critical role in LOAD and that several risk factors are still to be uncovered. Daw and colleagues had estimated the existence of four to seven additional genes contributing to this genetic variability (Daw et al., 2000).

Several GWAS in AD have now been published (Table 2). The first study of this type was performed by Grube et al., in which the approach used was to first generate a short list of candidate SNPs by analyzing > 17,000 SNPs in DNA

Table 2  
Main features and results of genome wide association studies performed in AD

Study	Platform	No. SNPs	Population	Genotype data publicly available	No. subjects		Replication stage(s)	Significant results
					Cases	Ctrls		
Grupe et al., 2007 (Grupe et al., 2007)	Celera (cSNPs)	17343	UK and USA	no	380	396	4 replication tiers (UK2, 309 cases+349 controls; UK3, 503 cases+643 controls; WU, 376 cases+344 controls; SD, 240 cases+330 controls) total number of samples (four tiers) = 1428 cases + 1666 controls	rs157581 (TOMM40, chr 19q13.32) rs405509 (APOE, chr 19q13.32) rs3745833 (GALP, chr 19q13.42) rs1554948 (TNK1, chr 17p13.1) rs1132899 (APOC2, chr 19q13.32) rs11622883 (14q32.13) rs8192708 (PCK1, chr 20q13.31) rs505058 (LMNA, chr 1q22) rs3800324 (PGBD1, chr 6p22.1) rs6907175 (LOC651924, chr 6q24.1) rs1859849 (7p15.2) rs41310885 (hCV22274641, FAM63A, chr 1q21.2) rs2074877 (MYH13, chr 17p13.1) rs41271951 (hCV15746640, CTSS, chr 1q21.2) rs444013 (UBD, chr 6p22.1) rs9608099 (BCR, chr 22q11.23) rs2882676 (ACAN, chr 15q26.1) rs13022344 (TRAK2, chr 2q33.1) rs11016976 (EBF3, chr 10q26.3) rs4420638 (APOC1, chr 19q13.32)
Coon et al., 2007 (Coon et al., 2007)	Affymetrix (500K)	502627	USA, Netherlands; overlaps with Reiman et al. (2007)	no	664	422	no	
Reiman et al., 2007 (Reiman et al., 2007)	Affymetrix (500K)	312316	USA, Netherlands; overlaps with Coon et al. (2007)	yes	446	290	neuropathological replication cohort (197 cases + 114 controls); clinical replication cohort (218 cases + 146 controls) total number of samples (two cohorts) = 415 cases + 260 controls	rs901104; rs1385600; rs1007837; rs2510038; rs4945261; rs7101429; rs10793294; rs4291702; rs7115850; rs2373115 (GAB2, chr 11q14.1)
Liu et al., 2007 (Liu et al., 2007)	Affymetrix (500K)	262000	Netherlands	no	103 LOAD patients and 170 first-degree relatives from a pedigree with 4645 members	4173 SNPs in 197 unrelated subjects from the GRIP population	Chr 1q25 (RGSL2, RALGPS2, C1orf49); Chr 3q22-24 (NMNAT3, CLSTN2); Chr 10q22-24 (HTR7, MPHOSPH1, CYP2C); Chr 11q25 (OPCML, HNT)	
Li et al., 2008 (Li et al., 2008)	Affymetrix (500K)	469438	Canada and UK	yes	753	736	120 SNPs in 418 cases + 249 controls	rs10868366; rs7019241 (GOLM1, chr 9q21.33) rs4420638 (APOC1, chr 19q13.32) also significant in Coon et al. (2007); rs10519262 (chr 15q21.2); rs9886784 (chr 9p24.3)

(continued on next page)

Table 2  
(continued)

Study	Platform	No. SNPs	Population	Genotype data publicly available	No. subjects		Replication stage(s)	Significant results
					Cases	Ctrls		
Abraham et al., 2008 (Abraham et al., 2008)	Illumina HumanHap300 + Illumina Sentrix HumanHap240S	561494	UK	no	1082 LOAD pooled	1239 controls pooled	114 SNPs were individually genotyped in the cases and controls used in the pools and 1400 controls were added	ApoE; rs727153 (~13 kb from the start of transcription of LRAT, chr 4q32.1), also showed increased significance (10-fold) when additional controls were combined
Bertram et al., 2008 (Bertram et al., 2008)	Affymetrix 500K	484522	self-reported European descent from NIMH Genetics Initiative Study sample	no	AD 1376 from 410 families		4 SNPs in 3 independent AD family samples: NIA- 1040 samples from 329 families; NCRAD- 1108 samples from 331 families; CAG- 483 samples from 215 sibships (total: 2689 samples 1816 affected and 845 unaffected)	Rs 4420638 (located 340 bp 3' of APC1 and probably reflects the effects of apoE E4 allele); rs 11159647 (in predicted gene NT_026437.1360, chr14q31.2), also significant in replication samples and in TGEN's data; rs179943 (in ATXN1, chr 6p22.3), trend for significance in replication samples; rs3826656 (in predicted gene NT_011109.848, chr 19q13.33), also significant in replication samples; rs2049161 (in cDNA BC040718, chr 18p11.31)
Beecham, 2009 (Beecham et al., 2009)	Illumina HumanHap550	532000	USA	no	492 load	496	1 SNP in 238 cases + 220 controls	ApoE; rs11610206 (downstream of FAM113B, chr 12q13), also significant in replication sample 1q42; 4q28; 6q14; 19q13
Carrasquillo et al., 2009 (Carrasquillo et al., 2009)	Illumina HumanHap300	313504	USA	no	844 load	1255	25 SNPs in 1547 cases + 1209 controls	ApoE; rs5984894, rs2573905 (in PCDH11X, chr Xq21.3), also significant in replication sample
Harold et al., 2009 (Harold et al., 2009)	Illumina 610 quad chip (Illumina HumanHap550 and HumanHap300 in some samples)	529205	Europe USA	yes	3941	7848	2 significant SNPs in 2023 cases + 2340 controls	ApoE; rs11136000 (in <i>CLU</i> , chr 8p21-p12), also significant in replication sample rs3851179 (5' of <i>PICALM</i> , chr 11q14, also significant in replication sample)
Lambert et al., 2009 (Lambert et al., 2009a)	Illumina human 610-quad BeadChip	537029	Europe	no	2032	5328	significant SNPs in 3978 probable AD cases + 3297 controls from Belgium, Finland, Italy and Spain	rs11136000, rs2279590, rs9331888 (in <i>CLU</i> , chr 8p21-p12), also significant in replication sample rs6656401 (in <i>CRI</i> , chr 1q32), also significant in replication sample

pools from one set of cases and controls. In truth, this study only covers a small proportion of the genome, probably around 5%, and is not strictly “genome-wide”. In this study, markers meeting a previously defined significance criteria were then typed in DNA pools from a second set of samples and, again the SNPs satisfying the criteria were then individually genotyped in four sets of cases and controls and finally in a fifth sample. In total, nearly 4,000 samples (~AD 2000 cases, ~2000 controls) from the USA and the UK were studied. Three SNPs on chromosome 19 in LD to APOE represented the most significant associations, of which two (rs157581 in *TOMM40* and rs405509 in *APOE*) achieved genome-wide significance. SNPs in other genes reached nominal significance but did not achieve genome wide significance (Grube et al., 2007).

The first studies covering most of the genome were published by Coon et al. (Coon et al., 2007) and Reiman et al. (Reiman et al., 2007) (~1,000 cases and controls). In these studies on largely the same dataset, only a single SNP in LD with APOE (rs4420638) reached genome wide significance although SNPs in *GAB2* (rs2373115) reached significance when the AD cases were stratified by *APOE* genotype (Reiman et al., 2007). An analysis of the top hits from AlzGene in the same dataset found that only SNPs in *ACE* reached nominal significance (Webster et al., 2009).

Liu et al. reported on a genome screen of 402 microsatellite markers in 103 LOAD patients and 170 first-degree relatives from a pedigree with 4,645 members from the Netherlands. Multipoint analysis revealed four significant (1q21, 1q25, 10q22-24 and 3q22-24) and one suggestive (11q24-25) linkage peaks. Several of these regions coincide with previously reported loci (Table 1) with the strongest linkage association found for chromosome 1q21. Following these results, the authors tested for association between cognitive function and 4,173 SNPs in the linked regions in an independent sample consisting of 197 individuals from the same Genetic Research in Isolated Populations program. After adjusting for multiple testing, significant associations were identified in four (1q25, 3q22-24, 10q22-24 and 11q25) of the previous five regions (Liu et al., 2007).

Abraham and colleagues performed a genome-wide association study in pooled DNA samples of ~2000 LOAD cases and > 1,000 controls. They identified a set of 109 SNPs with a significant association with AD and genotyped them individually. In addition to *APOE*, one SNP (rs727153), located approximately 13 kb apart from the start of *LRAT* transcription site, was suggested as associated with disease (Abraham et al., 2008).

Li et al. (2008) studied a hypothesis-generating cohort from Canada and identified rs4420638 within *APOC1* to be strongly associated with AD, due to LD with APOE (Coon et al., 2007) but nothing else reached genome wide significance (Li et al., 2008).

Bertram et al. (2008) used samples from 410 AD families to identify five SNPs significantly or marginally associated

with a multivariate phenotype combining age at onset of the disease and affection status. The marker presenting the most significant association was again rs4420638 (located 340 bp 3' of *APOC1*) and almost certainly reflecting the effects of APOE  $\epsilon$ 4 allele. Once more, no other SNP reached genome wide significance (Bertram et al., 2008).

Beecham and colleagues analyzed ~500 LOAD cases and ~500 cognitive controls followed by a further > 200 cases and > 200 controls used as a validation dataset for SNPs that reached nominal, but not genome-wide significance. They too, were able to confirm association with the *APOE* locus and they suggest an association with the 12q13 locus, which they replicated in the validation dataset. The associated SNP (rs11610206) is close to the hypothetical gene *FAM113B*. Additionally, there are some nearby candidate genes, such as *VDR* and *AMIGO2*. To validate associated SNPs with  $p$  values < 0.0001 and nominally associated candidate genes, they imputed SNPs from a previously published GWAS (Reiman et al., 2007). Four additional highly associated signals were replicated using the imputed dataset: 1q42 (within *DISC1*); 4q28 (200 kb proximal to *PCDH18*); 6q14 (nearest gene is *BCKDHB*); and 19q13 (within *ZNF224*) (Beecham et al., 2009).

By analyzing ~1,000 LOAD cases and ~1,000 controls and evaluating the 25 SNPs with the most significant allelic association in four additional series, Carrasquillo and colleagues suggested an association with the X chromosome SNP rs5984894 in *PCDH11X* (Xq21.3) (Carrasquillo et al., 2009) but again, this association did not reach genome wide significance.

Feulner et al. generated genome-wide data in a German cohort of ~AD 500 patients and ~500 controls. The results obtained were analyzed only for the genes included in the top results list on the AlzGene database. Additionally to APOE, nominally significant associations were found for six of the 10 studied genes (*CH25H*, *PGBD1*, *LMNA*, *PCK1*, *MAPT* and *SORL1*) (Feulner et al., 2009) but none of these putative signals reached genome wide significance.

All the above studies, which each used < 2,000 Alzheimer cases in their analysis, were able to pick up the signal at the APOE locus, but despite tantalizing results, none were able to identify other loci at a level which passes the threshold for genome wide significance, and no two of them identified the same locus. The data from the Reiman et al. and by Li et al. studies, were made publicly available ([www.tgen.org/research/neuro\\_gab2.cfm](http://www.tgen.org/research/neuro_gab2.cfm) and [www.GSK.com](http://www.GSK.com), respectively) to enable their additive use in other studies. Overall, these data pointed to the need for larger studies to identify risk loci with smaller effect sizes. Two such studies have now been reported.

One of these studies reported the analysis of ~4,000 cases and ~8,000 controls in Stage 1 and ~2000 cases and ~2000 controls in Stage 2. Two SNPs significantly associated with AD, outside the *APOE* locus, were identified: rs11136000 located in an intron of *CLU* on chromosome 8



and rs3851179 located close to the gene *PICALM* on chromosome 11. Although the risks associated with *CLU* and *PICALM* genes are relatively small (APOE odds ratio ~4; *CLU/PICALM* ~1.1) these associations reached genome wide significance (Harold et al., 2009). The other large AD GWAS reported on 2000 cases and ~5,000 controls in the first stage, and ~3,000 cases and ~3,000 controls in the replication stage. An association between AD and *ApoE*, *CLU* and *CR1* locus on chromosome 1q32 (OR = 1.2) was found (Lambert et al., 2009b).

These aforementioned genes (*CLU*, *CR1* and *PICALM*) will clearly be the subject of intense research. Here we will discuss the main features of each of these genes, as well as the potential pathobiological pathways in which they may be involved in the context of AD.

Clusterin or apolipoprotein J is, like APOE, a lipoprotein expressed in most mammalian tissues with higher levels present in brain, ovary, testis and liver (de Silva et al., 1990). *CLU* interacts with different molecules, including lipids, amyloid proteins, components of the complement membrane attack complex (MAC) and immunoglobulins (Jones and Jomary, 2002). Accordingly, it has been proposed to be involved in a number of physiological processes such as ongoing synapse turnover (Danik et al., 1993), apoptosis (Jenne and Tschopp, 1992; Wong et al., 1993), cytoprotection at fluid-tissue boundaries, membrane recycling during development and in response to injury and regulation of complement-mediated MAC (Jones and Jomary, 2002; Oda et al., 1994). Clusterin has also been proposed to be a form of secreted heat-shock protein or chaperone molecule (Michel et al., 1997; Wilson and Easterbrook-Smith, 2000).

Several lines of evidence suggest that *CLU* has a central (either protective or pathogenic) role in the pathway leading to Alzheimer's disease. First, *CLU* mRNA has been reported to be elevated in AD affected brain areas such as hippocampus, either when brains from AD patients were compared with one Huntington patient (Duguid et al., 1989), or to controls (May et al., 1990). Likewise, Oda et al. reported a statistically significant difference in the clusterin protein content of extracts from cortex and hippocampus when comparing 10 non-AD individuals and 25 AD patients (Oda et al., 1994). Second, clusterin is one of the components of amyloid plaques (Kida et al., 1995; McGeer et al., 1992; McGeer et al., 1994; Takamaru, 1994). Third, is able to bind soluble A $\beta$  through a specific, reversible and high-affinity interaction in cerebrospinal fluid (Ghisso et al., 1993; Golabek et al., 1995) to form complexes able to cross the blood–brain barrier by a high affinity receptor mediated process involving transcytosis (Zlokovic, 1996). Fourth, reduced levels of APOE and increased levels of *CLU* have been correlated with the number of E4 alleles, suggesting a compensatory induction of *CLU* in the brain of AD individuals with the  $\epsilon$ 4 allele of APOE presenting low brain levels of APOE (Bertrand et al., 1995). Moreover, *CLU* was

shown to prevent aggregation and polymerization of synthetic A $\beta$  and to enhance the oxidative stress caused by A $\beta$  *in vitro* (Matsubara et al., 1996; Oda et al., 1995), and to facilitate A $\beta$  uptake in cell culture experiments (Hammad et al., 1997). Clusterin appears to regulate the toxicity and conversion of A $\beta$  into soluble forms (Boggs et al., 1996; deMattos et al., 2002; Matsubara et al., 1996; Oda et al., 1995). Together with APOE, suppresses A $\beta$  deposition (deMattos et al., 2004) and may modify A $\beta$  clearance at the blood brain barrier (Bell et al., 2007). More recently we have established that common coding variability in *CLU* does not explain the association, and that there is no large effect of common genetic variability on expression in brain tissue. Our negative results lead us to hypothesize that the most likely mechanism underpinning the association is either small effects of genetic variability on resting gene expression, or effects on damage induced expression of the protein (Guerreiro et al., 2010).

*PICALM*, encodes the phosphatidylinositol-binding clathrin assembly protein, also known as *CALM*: clathrin assembly lymphoid-myeloid leukemia gene. It is ubiquitously expressed with particularly high levels in neurons. This gene has been associated with leukemia, thus its relation to AD may appear not as direct as the one observed for *CLU* (Fig. 1). Nonetheless, its involvement in clathrin-mediated endocytosis (essential to the intracellular trafficking of proteins and lipids) (Kim and Kim, 2001) and in the fusion of synaptic vesicles to the presynaptic membrane by directing the trafficking of VAMP2 (Harel et al., 2008) have lead Harold et al. to propose two interesting hypotheses for the role of *Picalm* in AD. In this way, genetic variability in *PICALM* may result on synapse perturbations, possibly through synaptic vesicle cycling, or on alterations of *APP* processing through endocytic pathways, culminating in changes in A $\beta$  levels (Harold et al., 2009). Interestingly, Harold et al. also showed a suggestive evidence for association with AD for the gene *BINI* (AMPH2, amphiphysin isoform 2, located on chromosome 2q14). This gene also encodes a protein known to be involved in synaptic vesicle endocytosis (Takei K., et al 1999) and is one of *Picalm* interactors' in Figure 1, reinforcing a role for these proteins in a new AD pathobiological pathway.

*CR1*, the complement component (3b/4b) receptor 1 (Knops blood group) is a member of the receptors of complement activation family. The gene encodes a monomeric single-pass Type I membrane glycoprotein found on erythrocytes, leukocytes, glomerular podocytes, and splenic follicular dendritic cells that mediates cellular binding to particles and immune complexes that have activated complement (Ahearn and Fearon, 1989).

Three complement pathways are known: the classical, alternative and lectin-mediated cascades, which have different activation triggers, but all terminate with the production of the membrane attack complex. High enough concentrations of MAC result in cell lysis. This may lead to tissue




Fig. 1. Predicted interactions for Clu (A), Picalm (B) and CR1 (C).

The software STRING 8.0 (available at [http://string.embl.de/newstring-cgi/show\\_input\\_page.pl? UserId=75H-1KjgP5Xi & sessionId=9vx3bNEK6tmB](http://string.embl.de/newstring-cgi/show_input_page.pl? UserId=75H-1KjgP5Xi & sessionId=9vx3bNEK6tmB)) was used to establish a network of predicted interactions for Clu (A), Picalm (B) and CR1 (C) proteins. Accessed in August 2009. STRING is a database of known and predicted protein interactions. The interactions include direct (physical) and indirect (functional) associations; they are derived from four sources: genomic context, high-throughput experiments, (conserved) coexpression and previous knowledge. STRING quantitatively integrates interaction data from these sources for a large number of organisms, and transfers information between these organisms where applicable. The database currently covers 2,483,276 proteins from 630 organisms.

damaging when the complement activation tight regulation, (that occurs through the action of several different endogenous complement inhibitor proteins), is deficient (Sjoberg et al., 2009). Typically, the complement classical pathway is the one associated with AD (Akiyama et al., 2000), mainly due to three facts: 1) C1q, the first protein in this pathway, efficiently binds to aggregated A $\beta$ , activating the pathway and further enhancing A $\beta$  aggregation and fibril formation (Rogers et al., 1992; Webster et al., 1995); 2) early complement activation proteins (C1q, C4 and C3) and the MAC have been found to colocalize with senile plaques, NFTs and dystrophic neurites in AD brains (McGeer et al., 1989; Veerhuis et al., 1996; Webster et al., 1997); and 3) increased mRNA levels of complement proteins are present in AD brains when compared with controls (Walker and McGeer, 1992). More recently, activation of the alternative pathway in AD brains has also been demonstrated: A $\beta$  activates the alternative pathway *in vitro* (Bradt et al., 1998); factor B mRNA is present in AD frontal cortex, and factor D cleaved split products of factor B (Bb and Ba) are significantly increased in AD brains (Strohmeier et al., 2000). After the discovery that the complement system can be activated in the brain by several senile plaques and neurofibrillary tangle related components, in the absence of antibodies, and that neurons are a source of complement proteins in the brain, the involvement of the complement system in AD has been widely accepted (McGeer and McGeer, 2001). However, whether this involvement has a protective or deleterious effect has been extensively debated. In fact, it has been proposed that binding of C1q to misfolded proteins in early AD, together with C4 binding protein, which decreases the activation of MAC providing the required physiological system balance, are favorable and enable clearance of the

misfolded material. But, when the system is overwhelmed by amyloid, this protein binds extensively to C1q leading to the full activation of the complement, ultimately leading to detrimental inflammation and neurodegeneration (Sjoberg et al., 2009).

In summary, as in other aging degenerative diseases, the complement system has an important role in AD, and one may expect that the activation of the classical or the alternative pathways (or both) by A $\beta$  will lead to neurodegeneration in individuals with a genetic predisposition (Zipfel, 2009). This will possibly result from an unbalance between the expression of regulator proteins, and one or more cascade proteins (Figure 2). This model is able to explain, at least partially, the presence of neuropathological changes in the brains of nondemented individuals (Hof et al., 1996) since the genetic variability in the complement genes may be responsible for different complement reactions to the presence of NFT and senile plaques. Interestingly, as mentioned above, one function attributed to clusterin is in the regulation of complement-mediated membrane attack complex. Together with vitronectin, clusterin binds to the nascent amphiphilic C5b-9 complex, rendering it water-soluble and lytically inactive, raising the possibility that the genetic risk conferred by clusterin for the development of AD, may arise from its regulation role in the complement system.

### 3. Vascular risk factors and Alzheimer's disease

These genetic findings point to the role of tissue and vascular damage in AD pathogenesis and thus to vascular risk factors in its etiology. It is noteworthy that many of the genes now implicated potentially have a direct role at the blood brain interface: this includes APOE, ACE and the

Fig. 2. Genetic variability and the role of the complement system in AD.

A $\beta$  and probably NFTs are able to activate the classical and alternative complement pathways. These are regulated by several membrane (m) and soluble (s) proteins at different stages. The genetic variability in *CR1* is now known to be associated with the risk of developing AD. Increased numbers of samples are needed to know if the same is true for any other component of these pathways. Drawn from the work of Tenner (Tenner, 2001) and McGeer and McGeer (McGeer and McGeer, 2002).

complement cascade components including CR1 and CLU. As such, these findings are consistent with the epidemiologic literature, which has consistently reported an association between vascular risk factors and AD. The evidence base for the prevention of AD and related brain pathologies is strongest for control of vascular risk factors (Gustafson D and Skoog I, 2009). Overweight and obesity is a cornerstone of vascular risk, which predisposes to hypertension, hypercholesterolemia, diabetes, and cardiovascular disease. Indeed, the low-risk ratios observed in genetic studies attempting to identify new susceptibility genes for AD may be due to lack of information on presence and/or severity of this vascular involvement, as well as to the differential expression and clustering of vascular and metabolic traits. AD brain pathologies exist against a background continuum of vascular pathologies, which may modulate risk for clinically manifest disease. Vascular factors most directly related to newly identified susceptibility genes are hypertension, hypercholesterolemia, and overweight and obesity.

Hypertension is a risk factor for stroke, ischemic white matter lesions, silent infarcts, general atherosclerosis, myocardial infarction and cardiovascular morbidity and mortality. This risk increases with increasing blood pressure also at apparently healthy blood pressure ranges (Kannel, 2000). Several longitudinal studies have suggested an association between AD and previous hypertension (Kivipelto et al., 2002; Launer et al., 2000; Qiu et al., 2005; Skoog et al.,

1996; Stewart et al., 2009). *ACE*, which is currently (accessed on 16th November) the fifth top hit on Alzgene database (Bertram et al., 2007), plays a classical role in blood pressure regulation as part of the renin-angiotensin system (Goossens et al., 2003). This system may play a role in dementia pathogenesis because of its effects on vascular and metabolic homeostasis, as well as amyloid metabolism. The gene encoding for ACE is an AD susceptibility gene whereby effect modification is observed by vascular phenotype, particularly with population stratification by vascular factors such as APOE  $\epsilon$ 4 allele, systolic blood pressure, body mass index, and obesity indexes (Gustafson et al., 2008; Katzov et al., 2004). Thus, the renin-angiotensin system may also provide a link between obesity, hypertension, and vascular syndromes, such as Type 2 diabetes, and health of the brain (Goossens et al., 2003; Katzov et al., 2004) because human brain and adipose tissue express the renin-angiotensin system (Strazzullo et al., 2003).

Cholesterol is important in AD, not only because of its relationship with cardiovascular disease, but due to its role in amyloid metabolism (Sparks et al., 1994). APOE and CLU are two proteins involved in lipid transport in the peripheral and central nervous systems (Nuutinen et al., 2009). APOE regulates cholesterol homeostasis in astrocytes and microglia, and is related to blood cholesterol levels (Hoglund and Blennow, 2007). In addition, mutations in the *APP* gene upregulate A $\beta$ 40 and A $\beta$ 42 production;

(Pangalos et al., 2005) and A $\beta$  processing is sensitive to cholesterol levels and lipid trafficking. Brain cholesterol levels increase during AD progression (Hoglund and Blennow, 2007). The epidemiologic evidence associating high blood cholesterol levels with AD and other forms of dementia is mixed. High cholesterol levels in midlife may increase risk for subsequent dementia and AD (Kivipelto et al., 2002; Notkola et al., 1998; Whitmer et al., 2005), however, in late-life, low cholesterol levels have been predictive of subsequent dementia (Mielke et al., 2005; Reitz et al., 2004) or no association has been observed (Li et al., 2005; Yoshitake et al., 1995). Nevertheless, even within the midlife cholesterol literature, results are conflicting, as some studies have not found high cholesterol to predict later dementia (Kalmijn et al., 2000; Stewart et al., 2007; Tan et al., 2003). While there remain a number of questions regarding the amyloid hypothesis in relationship to AD, the potential link to cholesterol metabolism and vascular damage is noteworthy (Hardy, 2009).

Finally, while overweight and obesity appear to increase risk for dementia independently of other vascular factors, there is limited evidence related to adipose-specific mechanisms of action in AD, particularly in relationship to these newly identified susceptibility genes. Midlife total or central obesity measured decades before dementia onset has been linked to higher risk of dementia in late life (Fitzpatrick et al., 2009; Gustafson et al., 2009; Kivipelto et al., 2005; Whitmer et al., 2007; Whitmer et al., 2008). Risky effects of high BMI as late as in the eighth decade of life have also been observed (Gustafson et al., 2003; Hayden et al., 2006). During the prodromal phase of dementia, higher rates of body weight or BMI decline occur among those developing dementia (Barrett-Connor et al., 1996; Buchman et al., 2005; Stewart et al., 2005). Thus, one cannot deny the role of excess adiposity as enhanced substrate for CR1-related inflammatory events, nor its potential role in hypertension and hyperlipidemia. However, also of importance are the implications of declining metabolic parameters, such as BMI (Barrett-Connor et al., 1996; Buchman et al., 2005; Stewart et al., 2005), blood pressure (Stewart et al., 2009) and cholesterol (Stewart et al., 2007) in AD, for which these newly identified susceptibility genes may enhance our precision in identifying subgroups of AD for whom interventions are more advantageous.

#### 4. Possible role of homozygosity and recessive cases

AD, as many other diseases occurring sporadically, recurs within families more often than expected by chance alone. However, in most of the cases, the pattern of familial recurrence is not compatible with simple Mendelian transmission and this model is typically presumed to reflect a multifactorial determination with contributions from multiple genes and/or environmental factors (Altshuler et al., 2008). However, the observed familial recurrence could

also be attributed to genetic loci with large phenotypic effects and reduced penetrance (possibly recessive loci). In this case, one would not necessarily expect to see recurrence of the disease in multiple generations, nor a high recurrence rate among siblings, and the disease would be sporadic in the population. Although without a definite confirmation of pathogenicity, two rare potentially disease-associated mutations (Q170H and R181G) in *ADAM10* (an alpha-secretase capable of anti-amyloidogenic proteolysis of the amyloid precursor protein) were recently reported to be associated with LOAD (Kim et al., 2009). Other mutations in *PSEN1* (A79V) (Kauwe et al., 2007) and *PSEN2* (N141I) (Levy-Lahad et al., 1995) have also been reported to be present in families with non-carriers affected individuals.

Recessive contributions can be inferred when populations with high degrees of consanguinity present higher prevalence of the disease than the general population (Mani et al., 2002). The Wadi Ara population is one example of this premise: an unusually high prevalence of AD (20% of those over 65 years and 60% of those over 85 years) in a population where the  $\epsilon 4$  allele of *APOE* is relatively uncommon (Bowirrat et al., 2000; Bowirrat et al., 2001). In this regard, the study of families with a recessive mode of inheritance may not only identify the cause of disease in the respective family, but also be of utility in the identification of risk factors contributing to the sporadic form of disease.

Populations that have been largely isolated and subjected to extensive inbreeding during considerable periods in their recent history represent a powerful resource for the study of new genetic variants for common diseases. These populations provide several advantages for genetic research, such as longer stretches of linkage between neighboring markers, high levels of genetic and environmental homogeneity and a simpler genetic architecture for complex traits. Although these long homozygous tracts of uninterrupted sequences may represent deletion polymorphisms, loss of heterozygosity or segmental uniparental disomy, recent data suggest that these, most likely, represent autozygosity (homozygosity by virtue of parental descent from a common ancestor) (Develee et al., 2001; Li et al., 2006; Raghavan et al., 2005; Woods et al., 2004). In this way, an obvious application of whole genome platforms in relation to autozygosity is in the genetic analysis of consanguineous families. This can be considered as an analogous approach to linkage analysis, in which researchers aim to define shared regions of autozygosity and/or overlapping structural variants to determine the role of autozygosity in a particular disease. Autozygosity mapping has long been recognized as a rapid and cost-effective way to identify loci underlying recessive disease (Lander and Botstein, 1987) and several genes underlying different disorders have been identified using this methodology (Camargos et al., 2008; Paisan-Ruiz et al., 2009). Specifically in AD, we have generated the first catalog of autozygosity in EOAD by studying a consanguineous Israeli family. Although we were unable to pinpoint a specific gene

due to the small number of samples we had available for analysis, we were able to generate a catalog that may be used in future studies of other families (Clarimon et al., 2008).

Furthermore, even in outbred populations, more individuals have a high frequency of these autozygous tracts than previously expected (Gibson et al., 2006; Li et al., 2006). Our group and others have recently reported the unexpected high degree of apparent parental consanguinity in control individuals from North America (~10% of studied individuals harboring homozygous tracts larger than 5 Mb) (Simon-Sanchez et al., 2007). Similar numbers (~6%) were presented by Li and collaborators, when studying an outbred population of unrelated Han Chinese (Li et al., 2006) and by Gibson et al. who reported that > 1,000 tracts exceeding 1 Mb in length were observed in the ~200 unrelated HapMap individuals studied (Gibson et al., 2006). These observations prompted us to study autozygosity in LOAD in an outbred population. By comparing measures of extended homozygosity (greater than 1 Mb in length) in a population of > 800 LOAD cases and > 550 controls we were able to identify one homozygous region on chromosome 8 (8p12, not including the *CLU* locus), significantly associated with LOAD. Additionally, the comparison of the total numbers of homozygous runs and the total length of these runs between cases and controls, revealed a suggestive difference in these measures ( $p$ -values 0.052–0.062), most likely symptomatic of a recessive component in the etiology of LOAD (Nalls et al., 2009). The role of recessive mutations in AD has been considerably overlooked: in addition to the recent works describing recessive *APP* mutations (discussed above in this review) (Di Fede et al., 2009; Tomiyama et al., 2008), only two other studies of isolated populations with a high incidence of the disease have been reported where the primary analyses were performed using dominant or additive modes of inheritance (Farrer et al., 2003; Liu et al., 2007). The new technologies now available will allow us to overcome this gap soon.

## 5. The next steps

Two major and clearly nonexclusive pathways have been recently discussed as the future guidelines in the genome wide analysis of complex disorders (Goldstein, 2009; Hirschhorn, 2009; Kraft and Hunter, 2009). The first is the extension of the assembly of studies containing larger (tens or even hundreds of thousands) and representative samples to identify variants with lower frequencies that may have been missed until now and that could explain the so elusive fractions of “missing heritability” in AD. The increase in the number of studied samples will inevitably result in the discovery of new variants and probably new genes associated with AD, but the real net value of these variants is highly disputable. Therefore, the actual dilemma now is to know how far one should take these studies to keep a

positive balance between the resources applied and the gathered genetic returns (Goldstein, 2009; Hardy and Singleton, 2009). Clearly, still to discover rare variants and variants with small effect sizes will be difficult to replicate, due to reduced power and restriction to specific populations, respectively. Nonetheless, to identify these rare variants one may speculate the need to use new chips with a better coverage of rare variants and the resequencing of previously identified regions. One may also predict that, being AD a complex disorder, more emphasis will be put in the study of endophenotypes, as happened in the study by Liu et al. that used cognitive function as an endophenotype of AD and identified the *RGSL2*, *RALGPS2* and *C1orf49* genes as potential causative genes located in one of the associated genomic regions (Liu et al., 2007). This approach will obviously require precise and clearly defined clinical assessments.

The second line of investigation will rely in the sequencing of whole exomes and whole genomes, expectantly unveiling several new rarer risk variants. These higher risk variants may be related to the commoner lower risk variants found with GWAS. In fact, a classical example comes from the study of Parkinson's disease genetics: rare high-risk variants in the  $\alpha$ -synuclein gene are the cause of monogenic PD (Polymeropoulos et al., 1997), while a common haplotype of this same gene has been established as a moderate risk cause of sporadic disease (Simon-Sanchez et al., 2009).

Both lines of research will be followed by large resequencing efforts, to identify the real risk variants. Many GWAS have identified regions of the genome associated with AD, but in many cases the real risk/causal changes are not known. Additionally, in the cases where SNPs have been associated with a disease, these SNPs identified may in fact be in LD with the real variants causing the association. Further functional data, (for instance, the effects of a determined variant in gene expression), although not always possible to obtain, will be essential not only to validate the previously identified variants, but also because many variants map to noncoding protein sequences, gene deserts, or genomic regions without any functional elements. The integration of these functional studies with information on multiple variants from the same gene, in different populations and the effects of epigenetics and epistasis will be vital. The interpretation of these results, however, will be complex and will most likely require the combination of disciplines as integrative genomics and systems biology. Although difficult, this approach will ultimately allow a more profound understanding of the molecular pathways underlying AD and AD risk, as well as the subsequent identification of effective biomarkers and drugs.

## Disclosure statement

None of the authors has any actual or potential conflicts of interest including any financial, personal or other rela-

tionships with other people or organizations within 3 years of beginning the work submitted that could inappropriately bias their work.

## Acknowledgements

This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project no. Z01 AG000950-06 and Fundacao para a Ciencia e Tecnologia, Portugal grant SFRH/BD/27,442/2006. DRG was supported by the Swedish MFR and JH by an MRC Returning Scientist Award.

## References

- Abraham, R., Moskvina, V., Sims, R., Hollingworth, P., Morgan, A., Georgieva, L., Dowzell, K., Cichon, S., Hillmer, A.M., O'Donovan, M.C., Williams, J., Owen, M.J., Kirov, G., 2008. A genome-wide association study for late-onset Alzheimer's disease using DNA pooling. *BMC Med Genomics* 1, 44.
- Ahearn, J.M., Fearon, D.T., 1989. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). *Adv Immunol* 46, 183–219.
- Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., McGeer, P.L., O'Banion, M.K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F.L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., Wyss-Coray, T., 2000. Inflammation and Alzheimer's disease. *Neurobiol Aging* 21, 383–421.
- Altshuler, D., Daly, M.J., Lander, E.S., 2008. Genetic mapping in human disease. *Science* 322, 881–888.
- Ashford, J.W., 2004. APOE genotype effects on Alzheimer's disease onset and epidemiology. *J Mol Neurosci* 23, 157–165.
- Ashley-Koch, A.E., Shao, Y., Rimmler, J.B., Gaskell, P.C., Welsh-Bohmer, K.A., Jackson, C.E., Scott, W.K., Haines, J.L., Pericak-Vance, M.A., 2005. An autosomal genomic screen for dementia in an extended Amish family. *Neurosci Lett* 379, 199–204.
- Avramopoulos, D., Fallin, M.D., Bassett, S.S., 2005. Linkage to chromosome 14q in Alzheimer's disease (AD) patients without psychotic symptoms. *Am J Med Genet B Neuropsychiatr Genet* 132B, 9–13.
- Bacanu, S.A., Devlin, B., Chowdari, K.V., deKosky, S.T., Nimgaonkar, V.L., Sweet, R.A., 2002. Linkage analysis of Alzheimer disease with psychosis. *Neurology* 59, 118–120.
- Barrett-Connor, E., Edelman, S.L., Corey-Bloom, J., Wiederholt, W.C., 1996. Weight loss precedes dementia in community-dwelling older adults. *J Am Geriatr Soc* 44, 1147–1152.
- Bassett, S.S., Avramopoulos, D., Fallin, D., 2002. Evidence for parent of origin effect in late-onset Alzheimer disease. *Am J Med Genet* 114, 679–686.
- Beecham, G.W., Martin, E.R., Li, Y.J., Slifer, M.A., Gilbert, J.R., Haines, J.L., Pericak-Vance, M.A., 2009. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. *Am J Hum Genet* 84, 35–43.
- Bekris, L.M., Galloway, N.M., Montine, T.J., Schellenberg, G.D., Yu, C.E., 2009. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. *Am J Med Genet B Neuropsychiatr Genet* 153B(2), 409–417.
- Bell, R.D., Sagare, A.P., Friedman, A.E., Bedi, G.S., Holtzman, D.M., Deane, R., Zlokovic, B.V., 2007. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. *J Cereb Blood Flow Metab* 27, 909–918.
- Bertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M.F., Schjeide, B.M., Hooli, B., Divito, J., Ionita, I., Jiang, H., Laird, N., Moscarillo, T., Ohlsen, K.L., Elliott, K., Wang, X., Hu-Lince, D., Ryder, M., Murphy, A., Wagner, S.L., Blacker, D., Becker, K.D., Tanzi, R.E., 2008. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am J Hum Genet* 83, 623–632.
- Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., Tanzi, R.E., 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat Genet* 39, 17–23.
- Bertram, L., Tanzi, R.E., 2008. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. *Nat Rev Neurosci* 9, 768–778.
- Bertrand, P., Poirier, J., Oda, T., Finch, C.E., Pasinetti, G.M., 1995. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. *Brain Res Mol Brain Res* 33, 174–178.
- Blacker, D., Bertram, L., Saunders, A.J., Moscarillo, T.J., Albert, M.S., Wiener, H., Perry, R.T., Collins, J.S., Harrell, L.E., Go, R.C., Mahoney, A., Beaty, T., Fallin, M.D., Avramopoulos, D., Chase, G.A., Folstein, M.F., McInnis, M.G., Bassett, S.S., Doheny, K.J., Pugh, E.W., Tanzi, R.E., 2003. Results of a high-resolution genome screen of 437 Alzheimer's disease families. *Hum Mol Genet* 12, 23–32.
- Blom, E.S., Viswanathan, J., Kilander, L., Helisalmi, S., Soininen, H., Lannfelt, L., Ingelsson, M., Glaser, A., Hiltunen, M., 2008. Low prevalence of *APP* duplications in Swedish and Finnish patients with early-onset Alzheimer's disease. *Eur J Hum Genet* 16, 171–175.
- Bodmer, W., Bonilla, C., 2008. Common and rare variants in multifactorial susceptibility to common diseases. *Nat Genet* 40, 695–701.
- Boggs, L.N., Fuson, K.S., Baez, M., Churgay, L., McClure, D., Becker, G., May, P.C., 1996. Clusterin (Apo J) protects against in vitro amyloid-beta (1–40) neurotoxicity. *J Neurochem* 67, 1324–1327.
- Bowirrat, A., Friedland, R.P., Chapman, J., Korczyn, A.D., 2000. The very high prevalence of AD in an Arab population is not explained by APOE epsilon4 allele frequency. *Neurology* 55, 731.
- Bowirrat, A., Treves, T.A., Friedland, R.P., Korczyn, A.D., 2001. Prevalence of Alzheimer's type dementia in an elderly Arab population. *Eur J Neurol* 8, 119–123.
- Bradt, B.M., Kolb, W.P., Cooper, N.R., 1998. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. *J Exp Med* 188, 431–438.
- Buchman, A.S., Wilson, R.S., Bienias, J.L., Shah, R.C., Evans, D.A., Bennett, D.A., 2005. Change in body mass index and risk of incident Alzheimer disease. *Neurology* 65, 892–897.
- Butler, A.W., Ng, M.Y., Hamshere, M.L., Forabosco, P., Wroe, R., Al-Chalabi, A., Lewis, C.M., Powell, J.F., 2009. Meta-analysis of linkage studies for Alzheimer's disease – a web resource. *Neurobiol Aging* 30, 1037–1047.
- Cabrejo, L., Guyant-Marechal, L., Laquerriere, A., Vercelletto, M., De la Fourniere, F., Thomas-Anterion, C., VERNY, C., Letournel, F., Pasquier, F., Vital, A., Checler, F., Frebourg, T., Campion, D., Hannequin, D., 2006. Phenotype associated with *APP* duplication in five families. *Brain* 129, 2966–2976.
- Camargos, S., Scholz, S., Simon-Sanchez, J., Paisan-Ruiz, C., Lewis, P., Hernandez, D., Ding, J., Gibbs, J.R., Cookson, M.R., Bras, J., Guerreiro, R., Oliveira, C.R., Lees, A., Hardy, J., Cardoso, F., Singleton, A.B., 2008. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. *Lancet Neurol* 7, 207–215.
- Cargill, M., Altshuler, D., Ireland, J., Sklar, P., Ardlie, K., Patil, N., Shaw, N., Lane, C.R., Lim, E.P., Kalyanaraman, N., Nemesh, J., Ziaugra, L., Friedland, L., Rolfe, A., Warrington, J., Lipshutz, R., Daley, G.Q.,

- Lander, E.S., 1999. Characterization of single-nucleotide polymorphisms in coding regions of human genes. *Nat Genet* 22, 231–238.
- Carrasquillo, M.M., Zou, F., Pankratz, V.S., Wilcox, S.L., Ma, L., Walker, L.P., Younkin, S.G., Younkin, C.S., Younkin, L.H., Bisceglia, G.D., Ertekin-Taner, N., Crook, J.E., Dickson, D.W., Petersen, R.C., Graff-Radford, N.R., Younkin, S.G., 2009. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. *Nat Genet* 41, 192–198.
- Chakravarti, A., 1999. Population genetics – making sense out of sequence. *Nat Genet* 21 suppl, 56–60.
- Chartier-Harlin, M.C., Parfitt, M., Legrain, S., Perez-Tur, J., Brousseau, T., Evans, A., Berr, C., Vidal, O., Roques, P., Gourlet, V., 1994. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. *Hum Mol Genet* 3, 569–574.
- Choudhry, S., Coyle, N.E., Tang, H., Salari, K., Lind, D., Clark, S.L., Tsai, H.J., Naqvi, M., Phong, A., Ung, N., Matallana, H., Avila, P.C., Casal, J., Torres, A., Nazario, S., Castro, R., Battle, N.C., Perez-Stable, E.J., Kwok, P.Y., Sheppard, D., Shriver, M.D., Rodriguez-Cintrón, W., Risch, N., Ziv, E., Burchard, E.G., 2006. Population stratification confounds genetic association studies among Latinos. *Hum Genet* 118, 652–664.
- Clarimon, J., Djaldetti, R., Lleo, A., Guerreiro, R.J., Molinuevo, J.L., Paisan-Ruiz, C., Gomez-Isla, T., Blesa, R., Singleton, A., Hardy, J., 2008. Whole genome analysis in a consanguineous family with early onset Alzheimer's disease. *Neurobiol Aging* 30, Nos. 12, 1986–1991.
- Coon, K.D., Myers, A.J., Craig, D.W., Webster, J.A., Pearson, J.V., Lince, D.H., Zismann, V.L., Beach, T.G., Leung, D., Bryden, L., Halperin, R.F., Marlowe, L., Kaleem, M., Walker, D.G., Ravid, R., Heward, C.B., Rogers, J., Papassotiropoulos, A., Reiman, E.M., Hardy, J., Stephan, D.A., 2007. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. *J Clin Psychiatry* 68, 613–618.
- Corbo, R.M., Scacchi, R., 1999. Apolipoprotein E (APOE) allele distribution in the world. Is APOE\* four a "thrifty" allele? *Ann Hum Genet* 63, 301–310.
- Corder, E.H., Saunders, A.M., Risch, N.J., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Jr, Rimmler, J.B., Locke, P.A., Conneally, P.M., Schmechel, K.E., 1994. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Genet* 7, 180–184.
- Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A., 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261, 921–923.
- Curtis, D., North, B.V., Sham, P.C., 2001. A novel method of two-locus linkage analysis applied to a genome scan for late onset Alzheimer's disease. *Ann Hum Genet* 65, 473–481.
- Danik, M., Chabot, J.G., Hassan-Gonzalez, D., Suh, M., Quirion, R., 1993. Localization of sulfated glycoprotein-two/clusterin mRNA in the rat brain by in situ hybridization. *J Comp Neurol* 334, 209–227.
- Daw, E.W., Payami, H., Nemens, E.J., Nochlin, D., Bird, T.D., Schellenberg, G.D., Wijsman, E.M., 2000. The number of trait loci in late-onset Alzheimer disease. *Am J Hum Genet* 66, 196–204.
- Dawn Teare, M., Barrett, J.H., 2005. Genetic linkage studies. *Lancet* 366, 1036–1044.
- de Silva, H.V., Harmony, J.A., Stuart, W.D., Gil, C.M., Robbins, J., 1990. Apolipoprotein J: structure and tissue distribution. *Biochemistry* 29, 5380–5389.
- De Strooper, B., 2003. Aph-one, Pen-two, and Nicastrin with Presenilin generate an active gamma-Secretase complex. *Neuron* 38, 9–12.
- deMattos, R.B., Cirrito, J.R., Parsadanian, M., May, P.C., O'Dell, M.A., Taylor, J.W., Harmony, J.A., Aronow, B.J., Bales, K.R., Paul, S.M., Holtzman, D.M., 2004. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. *Neuron* 41, 193–202.
- deMattos, R.B., O'Dell, M. A., Parsadanian, M., Taylor, J.W., Harmony, J.A., Bales, K.R., Paul, S.M., Aronow, B.J., Holtzman, D.M., 2002. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA* 99, 10843–10848.
- Devilee, P., Cleton-Jansen, A.M., Cornelisse, C.J., 2001. Ever since Knudson. *Trends Genet* 17, 569–573.
- Di Fede, G., Catania, M., Morbin, M., Rossi, G., Suardi, S., Mazzoleni, G., Merlin, M., Giovagnoli, A.R., Prioni, S., Erbetta, A., Falcone, C., Gobbi, M., Colombo, L., Bastone, A., Beeg, M., Manzoni, C., Francescucci, B., Spagnoli, A., Cantu, L., Del Favero, E., Levy, E., Salmona, M., Tagliavini, F., 2009. A recessive mutation in the *APP* gene with dominant-negative effect on amyloidogenesis. *Science* 323, 1473–1477.
- Duguid, J.R., Bohmont, C.W., Liu, N.G., Tourtellotte, W.W., 1989. Changes in brain gene expression shared by scrapie and Alzheimer disease. *Proc Natl Acad Sci USA* 86, 7260–7264.
- Esch, F.S., Keim, P.S., Beattie, E.C., Blacher, R.W., Culwell, A.R., Oltersdorf, T., McClure, D., Ward, P.J., 1990. Cleavage of amyloid beta peptide during constitutive processing of its precursor. *Science* 248, 1122–1124.
- Farrer, L.A., Bowirrat, A., Friedland, R.P., Waraska, K., Korczyn, A.D., Baldwin, C.T., 2003. Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. *Hum Mol Genet* 12, 415–422.
- Fearnhead, N.S., Winney, B., Bodmer, W.F., 2005. Rare variant hypothesis for multifactorial inheritance: susceptibility to colorectal adenomas as a model. *Cell Cycle* 4, 521–525.
- Feulner, T.M., Laws, S.M., Friedrich, P., Wagenpfeil, S., Wurst, S.H., Riehle, C., Kuhn, K.A., Krawczak, M., Schreiber, S., Nikolaus, S., Forstl, H., Kurz, A., Riemenschneider, M., 2009. Examination of the current top candidate genes for AD in a genome-wide association study. *Mol Psychiatry*.
- Fitzpatrick, A.L., Kuller, L.H., Lopez, O.L., Diehr, P., O'Meara, E.S., Longstreth, W.T., Jr, Luchsinger, J.A., 2009. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. *Arch Neurol* 66, 336–342.
- Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B., Mortimer, J.A., Berg, S., Fiske, A., Pedersen, N.L., 2006. Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry* 63, 168–174.
- Ghiso, J., Matsubara, E., Koudinov, A., Choi-Miura, N.H., Tomita, M., Wisniewski, T., Frangione, B., 1993. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. *Biochem J* 293, 27–30.
- Gibson, J., Morton, N.E., Collins, A., 2006. Extended tracts of homozygosity in outbred human populations. *Hum Mol Genet* 15, 789–795.
- Golabek, A., Marques, M.A., Lalowski, M., Wisniewski, T., 1995. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. *Neurosci Lett* 191, 79–82.
- Goldstein, D.B., 2009. Common genetic variation and human traits. *N Engl J Med* 360, 1696–1698.
- Goossens, G.H., Blaak, E.E., van Baak, M.A., 2003. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. *Obes Rev* 4, 43–55.
- Grupe, A., Abraham, R., Li, Y., Rowland, C., Hollingworth, P., Morgan, A., Jehu, L., Segurado, R., Stone, D., Schadt, E., Karnoub, M., Nowotny, P., Tacey, K., Catanese, J., Sninsky, J., Brayne, C., Rubinsztein, D., Gill, M., Lawlor, B., Lovestone, S., Holmans, P., O'Donovan, M., Morris, J.C., Thal, L., Goate, A., Owen, M.J., Williams, J., 2007. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. *Hum Mol Genet* 16, 865–873.
- Guerreiro, R.J., Baquero, M., Blesa, R., Boada, M., Bras, J.M., Bullido, M.J., Calado, A., Crook, R., Ferreira, C., Frank, A., Gomez-Isla, T.,

- Hernandez, I., Lleo, A., Machado, A., Martinez-Lage, P., Masdeu, J., Molina-Porcel, L., Molinuevo, J.L., Pastor, P., Perez-Tur, J., Relvas, R., Oliveira, C.R., Ribeiro, M.H., Rogaeva, E., Sa, A., Samaranch, L., Sanchez-Valle, R., Santana, I., Tarraga, L., Valdivieso, F., Singleton, A., Hardy, J., Clarimon, J., 2010. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and *APP*. *Neurobiol Aging* 31(5), 725–731.
- Guerreiro RJ, Beck J, Gibbs JR, Santana I, Rossor MN, Schott JM, Nalls MA, Ribeiro H, Santiago B, Fox NC, Oliveira C, Collinge J, Mead S, Singleton A, Hardy J. 2010 Genetic Variability in *CLU* and Its Association with Alzheimer's Disease. *PLoS ONE* 5(3): e9510. doi: 10.1371/journal.pone.0009510
- Gustafson, D. and Skoog, I., 2009. Control of vascular risk factors. In: Wahlund, T.E., Gauthier, S., Editors. *Vascular Dementia in Clinical Practice*. Cambridge University Press.
- Gustafson, D., Rothenberg, E., Blennow, K., Steen, B., Skoog, I., 2003. An 18-year follow-up of overweight and risk of Alzheimer disease. *Arch Intern Med* 163, 1524–1528.
- Gustafson, D.R., Backman, K., Waern, M., Ostling, S., Guo, X., Zandi, P., Mielke, M.M., Bengtsson, C., Skoog, I., 2009. Adiposity indicators and dementia over 32 years in Sweden. *Neurology* 73, 1559–1566.
- Gustafson, D.R., Melchior, L., Eriksson, E., Sundh, V., Blennow, K., Skoog, I., 2008. The ACE Insertion Deletion polymorphism relates to dementia by metabolic phenotype, APOEε4, and age of dementia onset. *Neurobiol Aging* 31, Nos. 6, 910–916.
- Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B.L., Lieberburg, I., Koo, E.H., Schenk, D., Teplow, D.B., 1992. Amyloid beta-peptide is produced by cultured cells during normal metabolism. *Nature* 359, 322–325.
- Hahs, D.W., McCauley, J.L., Crunk, A.E., McFarland, L.L., Gaskell, P.C., Jiang, L., Slifer, S.H., Vance, J.M., Scott, W.K., Welsh-Bohmer, K.A., Johnson, S.R., Jackson, C.E., Pericak-Vance, M.A., Haines, J.L., 2006. A genome-wide linkage analysis of dementia in the Amish. *Am J Med Genet B Neuropsychiatr Genet* 141B, 160–166.
- Hammad, S.M., Ranganathan, S., Loukinova, E., Twal, W.O., Argraves, W.S., 1997. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-two/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. *J Biol Chem* 272, 18644–18649.
- Hamshere, M.L., Holmans, P.A., Avramopoulos, D., Bassett, S.S., Blacker, D., Bertram, L., Wiener, H., Rochberg, N., Tanzi, R.E., Myers, A., Wavrant-De Vrieze, F., Go, R., Fallin, D., Lovestone, S., Hardy, J., Goate, A., O'Donovan, M., Williams, J., Owen, M.J., 2007. Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. *Hum Mol Genet* 16, 2703–2712.
- Hardy, J., 1997. Amyloid, the presenilins and Alzheimer's disease. *Trends Neurosci* 20, 154–159.
- Hardy, J., 2009. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. *J Neurochem* 110, 1129–1134.
- Hardy, J., Crook, R., 2001. Presenilin mutations line up along transmembrane alpha-helices. *Neurosci Lett* 306, 203–205.
- Hardy, J., Singleton, A., 2009. Genomewide association studies and human disease. *N Engl J Med* 360, 1759–1768.
- Harel, A., Wu, F., Mattson, M.P., Morris, C.M., Yao, P.J., 2008. Evidence for CALM in directing VAMP2 trafficking. *Traffic* 9, 417–429.
- Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M.L., Pahwa, J.S., Moskvin, V., Dowzell, K., Williams, A., Jones, N., Thomas, C., Stretton, A., Morgan, A.R., Lovestone, S., Powell, J., Proitsi, P., Lupton, M.K., Brayne, C., Rubinsztein, D.C., Gill, M., Lawlor, B., Lynch, A., Morgan, K., Brown, K.S., Passmore, P.A., Craig, D., McGuinness, B., Todd, S., Holmes, C., Mann, D., Smith, A.D., Love, S., Kehoe, P.G., Hardy, J., Mead, S., Fox, N., Rossor, M., Collinge, J., Maier, W., Jessen, F., Schurmann, B., van den Bussche, H., Heuser, I., Kornhuber, J., Wiltfang, J., Dichgans, M., Frolich, L., Hampel, H., Hull, M., Rujescu, D., Goate, A.M., Kauwe, J.S., Cruchaga, C., Nowotny, P., Morris, J.C., Mayo, K., Sleegers, K., Bettens, K., Engelborghs, S., De Deyn, P.P., Van Broeckhoven, C., Livingston, G., Bass, N.J., Gurling, H., McQuillin, A., Gwilliam, R., Deloukas, P., Al-Chalabi, A., Shaw, C.E., Tsolaki, M., Singleton, A.B., Guerreiro, R., Muhleisen, T.W., Nothen, M.M., Moebus, S., Jockel, K.H., Klopp, N., Wichmann, H.E., Carrasquillo, M.M., Pankratz, V.S., Younkin, S.G., Holmans, P.A., O'Donovan, M., Owen, M.J., Williams, J., 2009. Genome-wide association study identifies variants at *CLU* and *PICALM* associated with Alzheimer's disease. *Nat Genet* 41, 1088–1093.
- Hattersley, A.T., McCarthy, M.I., 2005. What makes a good genetic association study? *Lancet* 366, 1315–1323.
- Hayden, K.M., Zandi, P.P., Lyketsos, C.G., Khachaturian, A.S., Bastian, L.A., Charoonruk, G., Tschanz, J.T., Norton, M.C., Pieper, C.F., Munger, R.G., Breitner, J.C., Welsh-Bohmer, K.A., 2006. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. *Alzheimer Dis Assoc Disord* 20, 93–100.
- Henricson, A., Kall, L., Sonnhammer, E.L., 2005. A novel transmembrane topology of presenilin based on reconciling experimental and computational evidence. *FEBS J* 272, 2727–2733.
- Hirschhorn, J.N., 2009. Genomewide association studies – illuminating biologic pathways. *N Engl J Med* 360, 1699–1701.
- Hof, P.R., Glanakiopoulos, P., Bouras, C., 1996. The neuropathological changes associated with normal brain aging. *Histol Histopathol* 11, 1075–1088.
- Hoglund, K., Blennow, K., 2007. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease. *CNS Drugs* 21, 449–462.
- Hollingworth, P., Hamshere, M.L., Holmans, P.A., O'Donovan, M.C., Sims, R., Powell, J., Lovestone, S., Myers, A., deVrieze, F.W., Hardy, J., Goate, A., Owen, M., Williams, J., 2007. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. *Am J Med Genet B Neuropsychiatr Genet* 144B, 841–848.
- Holmans, P., Hamshere, M., Hollingworth, P., Rice, F., Tunstall, N., Jones, S., Moore, P., Wavrant DeVrieze, F., Myers, A., Crook, R., Compton, D., Marshall, H., Meyer, D., Shears, S., Booth, J., Ramic, D., Williams, N., Norton, N., Abraham, R., Kehoe, P., Williams, H., Rudrasingham, V., O'Donovan, M., Jones, L., Hardy, J., Goate, A., Lovestone, S., Owen, M., Williams, J., 2005. Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. *Am J Med Genet B Neuropsychiatr Genet* 135B, 24–32.
- Hyman, B.T., Hedley-Whyte, E.T., Rebeck, G.W., Vonsattel, J.P., West, H.L., Growdon, J.H., 1996. Apolipoprotein E epsilon4/four in a neuropathologically normal very elderly individual. *Arch Neurol* 53, 215.
- International HapMap Consortium, 2005. A haplotype map of the human genome. *Nature* 437(7063), 1299–1320.
- Ioannidis, J.P., Ntzani, E.E., Trikalinos, T.A., Contopoulos-Ioannidis, D.G., 2001. Replication validity of genetic association studies. *Nat Genet* 29, 306–309.
- Jenne, D.E., Tschopp, J., 1992. Clusterin: the intriguing guises of a widely expressed glycoprotein. *Trends Biochem Sci* 17, 154–159.
- Jones, S.E., Jomary, C., 2002. Clusterin. *Int J Biochem Cell Biol* 34, 427–431.
- Kalmijn, S., Foley, D., White, L., Burchfiel, C.M., Curb, J.D., Petrovitch, H., Ross, G.W., Havlik, R.J., Launer, L.J., 2000. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. *Arterioscler Thromb Vasc Biol* 20, 2255–2260.
- Kannel, W.B., 2000. Risk stratification in hypertension: new insights from the Framingham Study. *Am J Hypertens* 13, 3S–10S.
- Kasuga, K., Shimohata, T., Nishimura, A., Shiga, A., Mizuguchi, T., Tokunaga, J., Ohno, T., Miyashita, A., Kuwano, R., Matsumoto, N., Onodera, O., Nishizawa, M., Ikeuchi, T., 2009. Identification of independent *APP* locus duplication in Japanese patients with early-onset Alzheimer disease. *J Neurol Neurosurg Psychiatry* 80, 1050–1052.
- Katzov, H., Bennet, A.M., Kehoe, P., Wiman, B., Gatz, M., Blennow, K., Lenhard, B., Pedersen, N.L., de Faire, U., Prince, J.A., 2004. A cla-



- distic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. *Hum Mol Genet* 13, 2647–2657.
- Kauwe, J.S., Jacquot, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A.M., Holtzman, D.M., Morris, J.C., Goate, A.M., 2007. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. *Ann Neurol* 61, 446–453.
- Kehe, P., Wavrant-De Vrieze, F., Crook, R., Wu, W.S., Holmans, P., Fenton, I., Spurlock, G., Norton, N., Williams, H., Williams, N., Lovestone, S., Perez-Tur, J., Hutton, M., Chartier-Harlin, M.C., Shears, S., Roehl, K., Booth, J., Van Voorst, W., Ramic, D., Williams, J., Goate, A., Hardy, J., Owen, M.J., 1999. A full genome scan for late onset Alzheimer's disease. *Hum Mol Genet* 8, 237–245.
- Kida, E., Choi-Miura, N.H., Wisniewski, K.E., 1995. Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. *Brain Res* 685, 211–216.
- Kim, J.A., Kim, H.L., 2001. Cell-free expression and functional reconstitution of CALM in clathrin assembly. *Exp Mol Med* 33, 89–94.
- Kim, M., Suh, J., Romano, D., Truong, M.H., Mullin, K., Hooli, B., Norton, D., Tesco, G., Elliott, K., Wagner, S.L., Moir, R.D., Becker, K.D., Tanzi, R.E., 2009. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate  $\alpha$ -secretase activity. *Hum Mol Genet* 18, 3987–3996.
- Kivipelto, M., Laakso, M.P., Tuomilehto, J., Nissinen, A., Soininen, H., 2002. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. *CNS Drugs* 16, 435–444.
- Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kareholt, I., Winblad, B., Helkala, E.L., Tuomilehto, J., Soininen, H., Nissinen, A., 2005. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. *Arch Neurol* 62, 1556–1560.
- Kovacs, D.M., Fausett, H.J., Page, K.J., Kim, T.W., Moir, R.D., Merriam, D.E., Hollister, R.D., Hallmark, O.G., Mancini, R., Felsenstein, K.M., Hyman, B.T., Tanzi, R.E., Wasco, W., 1996. Alzheimer-associated presenilins one and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. *Nat Med* 2, 224–229.
- Kraft, P., Hunter, D.J., 2009. Genetic risk prediction – are we there yet? *N Engl J Med* 360, 1701–1703.
- Lambert, J.C., Araria-Goumidi, L., Myllykangas, L., Ellis, C., Wang, J.C., Bullido, M.J., Harris, J.M., Artiga, M.J., Hernandez, D., Kwon, J.M., Frigard, B., Petersen, R.C., Cumming, A.M., Pasquier, F., Sastre, I., Tienari, P.J., Frank, A., Sulkava, R., Morris, J.C., St Clair, D., Mann, D.M., Wavrant-DeVrieze, F., Ezquerra-Trabalón, M., Amouyel, P., Hardy, J., Haltia, M., Valdivieso, F., Goate, A.M., Perez-Tur, J., Lendon, C.L., Chartier-Harlin, M.C., 2002. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. *Neurology* 59, 59–66.
- Lambert, J.C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M.J., Tavernier, B., Letenneur, L., Bettens, K., Berr, C., Pasquier, F., Fievet, N., Barberger-Gateau, P., Engelborghs, S., De Deyn, P., Mateo, I., Franck, A., Helisalmi, S., Porcellini, E., Hanon, O., de Pancorbo, M.M., Lendon, C., Dufouil, C., Jaillard, C., Leveillard, T., Alvarez, V., Bosco, P., Mancuso, M., Panza, F., Nacmias, B., Bossu, P., Piccardi, P., Annoni, G., Seripa, D., Galimberti, D., Hannequin, D., Licastro, F., Soininen, H., Ritchie, K., Blanche, H., Dartigues, J.F., Tzourio, C., Gut, I., Van Broeckhoven, C., Alperovitch, A., Lathrop, M., Amouyel, P., 2009a. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* 41, 1094–1099.
- Lambert, J.C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M.J., Tavernier, B., Letenneur, L., Bettens, K., Berr, C., Pasquier, F., Fievet, N., Barberger-Gateau, P., Engelborghs, S., De Deyn, P., Mateo, I., Franck, A., Helisalmi, S., Porcellini, E., Hanon, O., de Pancorbo, M.M., Lendon, C., Dufouil, C., Jaillard, C., Leveillard, T., Alvarez, V., Bosco, P., Mancuso, M., Panza, F., Nacmias, B., Bossu, P., Piccardi, P., Annoni, G., Seripa, D., Galimberti, D., Hannequin, D., Licastro, F., Soininen, H., Ritchie, K., Blanche, H., Dartigues, J.F., Tzourio, C., Gut, I., Van Broeckhoven, C., Alperovitch, A., Lathrop, M., Amouyel, P., 2009b. Genome-Wide Association Study Identifies Variants at CLU and CR1 Associated With Alzheimer's Disease. *Nat Genet* 41(10), 1094–1099.
- Lambert, J.C., Perez-Tur, J., Dupire, M.J., Galasko, D., Mann, D., Amouyel, P., Hardy, J., Delacourte, A., Chartier-Harlin, M.C., 1997. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. *Hum Mol Genet* 6, 2151–2154.
- Lander, E.S., 1996. The new genomics: global views of biology. *Science* 274, 536–539.
- Lander, E.S., Botstein, D., 1987. Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. *Science* 236, 1567–1570.
- Laudon, H., Hansson, E.M., Melen, K., Bergman, A., Farmery, M.R., Winblad, B., Lendahl, U., von Heijne, G., Naslund, J., 2005. A nine-transmembrane domain topology for presenilin 1. *J. Biol Chem* 280, 35352–35360.
- Launer, L.J., Ross, G.W., Petrovitch, H., Masaki, K., Foley, D., White, L.R., Havlik, R.J., 2000. Midlife blood pressure and dementia: the Honolulu-Asia aging study. *Neurobiol Aging* 21, 49–55.
- Lee, J.H., Cheng, R., Graff-Radford, N., Foroud, T., Mayeux, R., 2008. Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci. *Arch Neurol* 65, 1518–1526.
- Lee, J.H., Cheng, R., Santana, V., Williamson, J., Lantigua, R., Medrano, M., Arriaga, A., Stern, Y., Tycko, B., Rogaeva, E., Wakutani, Y., Kawarai, T., St George-Hyslop, P., Mayeux, R., 2006. Expanded genomewide scan implicates a novel locus at 3q28 among Caribbean hispanics with familial Alzheimer disease. *Arch Neurol* 63, 1591–1598.
- Lee, J.H., Mayeux, R., Mayo, D., Mo, J., Santana, V., Williamson, J., Flaquer, A., Ciappa, A., Rondon, H., Estevez, P., Lantigua, R., Kawarai, T., Toulina, A., Medrano, M., Torres, M., Stern, Y., Tycko, B., Rogaeva, E., St George-Hyslop, P., Knowles, J.A., 2004. Fine mapping of 10q and 18q for familial Alzheimer's disease in Caribbean Hispanics. *Mol Psychiatry* 9, 1042–1051.
- Levy-Lahad, E., Poorkaj, P., Wang, K., Fu, Y.H., Oshima, J., Mulligan, J., Schellenberg, G.D., 1996. Genomic structure and expression of STM2, the chromosome 1 familial Alzheimer disease gene. *Genomics* 34, 198–204.
- Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D.M., Oshima, J., Pettingell, W.H., Yu, C.E., Jondro, P.D., Schmidt, S.D., Wang, K., 1995. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 269, 973–977.
- Li, G., Shofer, J.B., Kukull, W.A., Peskind, E.R., Tsuang, D.W., Breitner, J.C., McCormick, W., Bowen, J.D., Teri, L., Schellenberg, G.D., Larson, E.B., 2005. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. *Neurology* 65, 1045–1050.
- Li, H., Wetten, S., Li, L., St Jean, P.L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M.R., Briley, J.D., Borrie, M., Coletta, N., deLisle, R., Dhalla, D., Ehm, M.G., Feldman, H.H., Fornazzari, L., Gauthier, S., Goodgame, N., Guzman, D., Hammond, S., Hollingworth, P., Hsiung, G.Y., Johnson, J., Kelly, D.D., Keren, R., Kertesz, A., King, K.S., Lovestone, S., Loy-English, I., Matthews, P.M., Owen, M.J., Plumptre, M., Pryse-Phillips, W., Prinjha, R.K., Richardson, J.C., Saunders, A., Slater, A.J., St George-Hyslop, P.H., Stinnett, S.W., Swartz, J.E., Taylor, R.L., Wherrett, J., Williams, J., Yarnall, D.P., Gibson, R.A., Irizarry, M.C., Middleton, L.T., Roses, A.D., 2008. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. *Arch Neurol* 65, 45–53.
- Li, L.H., Ho, S.F., Chen, C.H., Wei, C.Y., Wong, W.C., Li, L.Y., Hung, S.I., Chung, W.H., Pan, W.H., Lee, M.T., Tsai, F.J., Chang, C.F., Wu, J.Y., Chen, Y.T., 2006. Long contiguous stretches of homozygosity in the human genome. *Hum Mutat* 27, 1115–1121.

- Li, Y.J., Scott, W.K., Hedges, D.J., Zhang, F., Gaskell, P.C., Nance, M.A., Watts, R.L., Hubble, J.P., Koller, W.C., Pahwa, R., Stern, M.B., Hiner, B.C., Jankovic, J., Allen, F.A., Jr, Goetz, C.G., Mastaglia, F., Stajich, J.M., Gibson, R.A., Middleton, L.T., Saunders, A.M., Scott, B.L., Small, G.W., Nicodemus, K.K., Reed, A.D., Schmechel, D.E., Welsh-Bohmer, K.A., Conneally, P.M., Roses, A.D., Gilbert, J.R., Vance, J.M., Haines, J.L., Pericak-Vance, M.A., 2002. Age at onset in two common neurodegenerative diseases is genetically controlled. *Am J Hum Genet* 70, 985–993.
- Liu, F., Arias-Vasquez, A., Sleegers, K., Aulchenko, Y.S., Kayser, M., Sanchez-Juan, P., Feng, B.J., Bertoli-Avella, A.M., van Swieten, J., Axenovich, T.I., Heutink, P., van Broeckhoven, C., Oostra, B.A., van Duijn, C.M., 2007. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. *Am J Hum Genet* 81, 17–31.
- Mahley, R.W., 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* 240, 622–630.
- Mahley, R.W., Rall, S.C., Jr, 2000. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev Genomics Hum Genet* 1, 507–537.
- Mani, A., Meraji, S.M., Houshyar, R., Radhakrishnan, J., Mani, A., Ahangar, M., Rezaie, T.M., Taghavinejad, M.A., Broumand, B., Zhao, H., Nelson-Williams, C., Lifton, R.P., 2002. Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus. *Proc Natl Acad Sci USA* 99, 15054–15059.
- Matsubara, E., Soto, C., Governale, S., Frangione, B., Ghiso, J., 1996. Apolipoprotein J and Alzheimer's amyloid beta solubility. *Biochem J* 316, 671–679.
- May, P.C., Lampert-Etchells, M., Johnson, S.A., Poirier, J., Masters, J.N., Finch, C.E., 1990. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. *Neuron* 5(6), 831–839.
- McGeer, E.G., McGeer, P.L., 2001. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. *Mol Interv* 1, 22–29.
- McGeer, P.L., Akiyama, H., Itagaki, S., McGeer, E.G., 1989. Activation of the classical complement pathway in brain tissue of Alzheimer patients. *Neurosci Lett* 107, 341–346.
- McGeer, P.L., Kawamata, T., Walker, D.G., 1992. Distribution of clusterin in Alzheimer brain tissue. *Brain Res* 579, 337–341.
- McGeer, P.L., Klegeris, A., Walker, D.G., Yasuhara, O., McGeer, E.G., 1994. Pathological proteins in senile plaques. *Tohoku J Exp Med* 174, 269–277.
- McGeer, P.L., McGeer, E.G., 2002. The possible role of complement activation in Alzheimer disease. *Trends Mol Med* 8, 519–523.
- Michel, D., Chatelain, G., North, S., Brun, G., 1997. Stress-induced transcription of the clusterin/apoJ gene. *Biochem J* 328, 45–50.
- Mielke, M.M., Zandi, P.P., Sjogren, M., Gustafson, D., Ostling, S., Steen, B., Skoog, I., 2005. High total cholesterol levels in late life associated with a reduced risk of dementia. *Neurology* 64, 1689–1695.
- Myers, A., Wavrant De-Vrieze, F., Holmans, P., Hamshere, M., Crook, R., Compton, D., Marshall, H., Meyer, D., Shears, S., Booth, J., Ramic, D., Knowles, H., Morris, J.C., Williams, N., Norton, N., Abraham, R., Kehoe, P., Williams, H., Rudrasingham, V., Rice, F., Giles, P., Tunstall, N., Jones, L., Lovestone, S., Williams, J., Owen, M.J., Hardy, J., Goate, A., 2002. Full genome screen for Alzheimer disease: stage II analysis. *Am J Med Genet* 114, 235–244.
- Nalls, M.A., Guerreiro, R.J., Simon-Sanchez, J., Bras, J.T., Traynor, B.J., Gibbs, J.R., Launer, L., Hardy, J., Singleton, A.B., 2009. Extended tracts of homozygosity identify novel candidate genes associated with late-onset Alzheimer's disease. *Neurogenetics* 10, Nos. 3, 183–190.
- Notkola, I.L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., Nissinen, A., 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. *Neuroepidemiology* 17, 14–20.
- Nuutinen, T., Suuronen, T., Kauppinen, A., Salminen, A., 2009. Clusterin: A forgotten player in Alzheimer's disease. *Brain Res Rev* 61, Nos. 2, 89–104.
- Oda, T., Pasinetti, G.M., Osterburg, H.H., Anderson, C., Johnson, S.A., Finch, C.E., 1994. Purification and characterization of brain clusterin. *Biochem Biophys Res Commun* 204, 1131–1136.
- Oda, T., Wals, P., Osterburg, H.H., Johnson, S.A., Pasinetti, G.M., Morgan, T.E., Rozovsky, I., Stine, W.B., Snyder, S.W., Holzman, T.F., 1995. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1–42) and forms slowly sedimenting A beta complexes that cause oxidative stress. *Exp Neurol* 136, 22–31.
- Olson, J.M., Goddard, K.A., Dudek, D.M., 2002. A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. *Am J Hum Genet* 71, 154–161.
- Paisan-Ruiz, C., Bhatia, K.P., Li, A., Hernandez, D., Davis, M., Wood, N.W., Hardy, J., Houlden, H., Singleton, A., Schneider, S.A., 2009. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. *Ann Neurol* 65, 19–23.
- Pangalos, M.N., Jacobsen, S.J., Reinhart, P.H., 2005. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. *Biochem Soc Trans* 33, 553–558.
- Pedersen, N.L., Posner, S.F., Gatz, M., 2001. Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. *Am J Med Genet* 105, 724–728.
- Pericak-Vance, M.A., Bass, M.P., Yamaoka, L.H., Gaskell, P.C., Scott, W.K., Terwedow, H.A., Menold, M.M., Conneally, P.M., Small, G.W., Vance, J.M., Saunders, A.M., Roses, A.D., Haines, J.L., 1997. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. *JAMA* 278, 1237–1241.
- Pericak-Vance, M.A., Grubber, J., Bailey, L.R., Hedges, D., West, S., Santoro, L., Kemmerer, B., Hall, J.L., Saunders, A.M., Roses, A.D., Small, G.W., Scott, W.K., Conneally, P.M., Vance, J.M., Haines, J.L., 2000. Identification of novel genes in late-onset Alzheimer's disease. *Exp Gerontol* 35, 1343–1352.
- Podewils, L.J., Guallar, E., Kuller, L.H., Fried, L.P., Lopez, O.L., Carlson, M., Lyketsos, C.G., 2005. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. *Am J Epidemiol* 161, 639–651.
- Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., Nussbaum, R.L., 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276, 2045–2047.
- Qiu, C., Winblad, B., Fratiglioni, L., 2005. The age-dependent relation of blood pressure to cognitive function and dementia. *Lancet Neurol* 4, 487–499.
- Rademakers, R., Cruts, M., Van Broeckhoven, C., 2003. Genetics of early-onset Alzheimer dementia. *Scientific World Journal*, 3497–3519.
- Raghavan, M., Lillington, D.M., Skoulakis, S., Debernardi, S., Chaplin, T., Foot, N.J., Lister, T.A., Young, B.D., 2005. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. *Cancer Res* 65, 375–378.
- Raux, G., Guyant-Marechal, L., Martin, C., Bou, J., Penet, C., Brice, A., Hannequin, D., Frebourg, T., Campion, D., 2005. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. *J Med Genet* 42, 793–795.
- Reiman, E.M., Webster, J.A., Myers, A.J., Hardy, J., Dunckley, T., Zismann, V.L., Joshipura, K.D., Pearson, J.V., Hu-Lince, D., Huentelman, M.J., Craig, D.W., Coon, K.D., Liang, W.S., Herbert, R.H., Beach, T., Rohrer, K.C., Zhao, A.S., Leung, D., Bryden, L., Marlowe, L., Kaleem, M., Mastroeni, D., Grover, A., Heward, C.B., Ravid, R., Rogers, J., Hutton, M.L., Melquist, S., Petersen, R.C., Alexander, G.E., Caselli, R.J., Kukull, W., Papassotriopoulos, A., Stephan, D.A., 2007. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. *Neuron* 54, 713–720.

- Reitz, C., Tang, M.X., Luchsinger, J., Mayeux, R., 2004. Relation of plasma lipids to Alzheimer disease and vascular dementia. *Arch Neurol* 61, 705–714.
- Remes, A.M., Finnila, S., Mononen, H., Tuominen, H., Takalo, R., Herva, R., Majamaa, K., 2004. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. *Neurology* 63, 234–240.
- Rogaev, E.I., Sherrington, R., Rogaeva, E.A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., 1995. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. *Nature* 376, 775–778.
- Rogaeva, E., 2002. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. *Neuromol Med* 2, 1–10.
- Rogers, J., Cooper, N.R., Webster, S., Schultz, J., McGeer, P.L., Styren, S.D., Civin, W.H., Brachova, L., Bradt, B., Ward, P., 1992. Complement activation by beta-amyloid in Alzheimer disease. *Proc Natl Acad Sci USA* 89, 10016–10020.
- Rovelet-Lecrux, A., Frebourg, T., Tuominen, H., Majamaa, K., Campion, D., Remes, A.M., 2007. *APP* locus duplication in a Finnish family with dementia and intracerebral haemorrhage. *J Neurol Neurosurg Psychiatry* 78, 1158–1159.
- Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., Dumanchin, C., Feuillet, S., Brice, A., Vercelletto, M., Dubas, F., Frebourg, T., Campion, D., 2006. *APP* locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. *Nat Genet* 38, 24–26.
- Sanan, D.A., Weisgraber, K.H., Russell, S.J., Mahley, R.W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., Roses, A.D., 1994. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. *J Clin Invest* 94, 860–869.
- Sayed-Tabatabaie, F.A., Houwing-Duistermaat, J.J., van Duijn, C.M., Witteman, J.C., 2003. Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. *Stroke* 34, 1634–1639.
- Scott, W.K., Hauser, E.R., Schmechel, D.E., Welsh-Bohmer, K.A., Small, G.W., Roses, A.D., Saunders, A.M., Gilbert, J.R., Vance, J.M., Haines, J.L., Pericak-Vance, M.A., 2003. Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. *Am J Hum Genet* 73, 1041–1051.
- Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* 375, 754–760.
- Shoji, M., Golde, T.E., Ghiso, J., Cheung, T.T., Estus, S., Shaffer, L.M., Cai, X.D., McKay, D.M., Tintner, R., Frangione, B., 1992. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. *Science* 258, 126–129.
- Siest, G., Pillot, T., Regis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M.M., Visvikis, S., 1995. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. *Clin Chem* 41, 1068–1086.
- Sillen, A., Andrade, J., Lilius, L., Forsell, C., Axelman, K., Odeberg, J., Winblad, B., Graff, C., 2008. Expanded high-resolution genetic study of 109 Swedish families with Alzheimer's disease. *Eur J Hum Genet* 16, 202–208.
- Simon-Sanchez, J., Scholz, S., Fung, H.C., Matarin, M., Hernandez, D., Gibbs, J.R., Britton, A., de Vries, F.W., Peckham, E., Gwinn-Hardy, K., Crawley, A., Keen, J.C., Nash, J., Borgaonkar, D., Hardy, J., Singleton, A., 2007. Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. *Hum Mol Genet* 16, 1–14.
- Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G., Kruger, R., Federoff, M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M.A., Illig, T., Gieger, C., Houlden, H., Steffens, M., Okun, M.S., Racette, B.A., Cookson, M.R., Foote, K.D., Fernandez, H.H., Traynor, B.J., Schreiber, S., Arepalli, S., Zonozzi, R., Gwinn, K., van der Brug, M., Lopez, G., Chanock, S.J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X., Wood, N.W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J.A., Singleton, A.B., Gasser, T., 2009. Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nat Genet* 41, 1308–1312.
- Simon-Sanchez, J., Singleton, A., 2008. Genome-wide association studies in neurological disorders. *Lancet Neurol* 7, 1067–1072.
- Sjoberg, A.P., Trouw, L.A., Blom, A.M., 2009. Complement activation and inhibition: a delicate balance. *Trends Immunol* 30, 83–90.
- Skoog, I., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.A., Nilsson, L., Persson, G., Oden, A., Svanborg, A., 1996. 15-year longitudinal study of blood pressure and dementia. *Lancet* 347, 1141–1145.
- Sleegers, K., Brouwers, N., Gijselincx, I., Theuns, J., Goossens, D., Wauters, J., Del-Favero, J., Cruts, M., van Duijn, C.M., Van Broeckhoven, C., 2006. *APP* duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. *Brain* 129, 2977–2983.
- Sparks, D.L., Scheff, S.W., Hunsaker, J.C., 3rd, Liu, H., Landers, T., Gross, D.R., 1994. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. *Exp Neurol* 126, 88–94.
- Staessen, J.A., Wang, J.G., Ginocchio, G., Petrov, V., Saavedra, A.P., Soubrier, F., Vlietinck, R., Fagard, R., 1997. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. *J Hypertens* 15, 1579–1592.
- Stewart, R., Masaki, K., Xue, Q.L., Peila, R., Petrovitch, H., White, L.R., Launer, L.J., 2005. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. *Arch Neurol* 62, 55–60.
- Stewart, R., White, L.R., Xue, Q.L., Launer, L.J., 2007. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. *Arch Neurol* 64, 103–107.
- Stewart, R., Xue, Q.L., Masaki, K., Petrovitch, H., Ross, G.W., White, L.R., Launer, L.J., 2009. Change in blood pressure and incident dementia: a 32-year prospective study. *Hypertension* 54, 233–240.
- Strazzullo, P., Iacone, R., Iacoviello, L., Russo, O., Barba, G., Russo, P., D'Orazio, A., Barbato, A., Cappuccio, F.P., Farinaro, E., Siani, A., 2003. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. *Ann Intern Med* 138, 17–23.
- Strittmatter, W.J., Weisgraber, K.H., Goedert, M., Saunders, A.M., Huang, D., Corder, E.H., Dong, L.M., Jakes, R., Alberts, M.J., Gilbert, J.R. et al., 1994. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. *Exp Neurol* 125, 163–171.
- Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.M., Salvesen, G.S., Pericak-Vance, M., Schmechel, D., Saunders, A.M., Goldgaber, D., Roses, A.D., 1993. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. *Proc Natl Acad Sci USA* 90, 8098–8102.
- Strohmeier, R., Shen, Y., Rogers, J., 2000. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. *Brain Res Mol Brain Res* 81, 7–18.
- Takamaru, Y., 1994. [Analysis of the 80 kDa antigen in senile plaque amyloid]. *Hokkaido Igaku Zasshi* 69, 191–201.
- Takei K, Slepnev VI, Haucke V, De Camilli P. 1999 Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. *Nat Cell Biol.* 1999 May;1(1):33–9.
- Tan, Z.S., Seshadri, S., Beiser, A., Wilson, P.W., Kiel, D.P., Tocco, M., D'Agostino, R.B., Wolf, P.A., 2003. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. *Arch Intern Med* 163, 1053–1057.

- Tenner, A.J., 2001. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. *Neurobiol Aging* 22, 849–861.
- Tian, C., Gregersen, P.K., Seldin, M.F., 2008. Accounting for ancestry: population substructure and genome-wide association studies. *Hum Mol Genet* 17, R143–R150.
- Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., Wada, Y., Yoshioka, E., Nishizaki, T., Watanabe, Y., Mori, H., 2008. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. *Ann Neurol* 63, 377–387.
- Veerhuis, R., Janssen, I., Hack, C.E., Eikelenboom, P., 1996. Early complement components in Alzheimer's disease brains. *Acta Neuropathol* 91, 53–60.
- Walker, D.G., McGeer, P.L., 1992. Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. *Brain Res Mol Brain Res* 14, 109–116.
- Webster, J., Myers, A., Reiman, E.M., Zismann, V.L., Joshipura, K.D., Pearson, J.V., Hu-Lince, D., Huentelman, M.J., Craig, D.W., Coon, K.D., Beach, T., Roher, K.C., Zhao, A.S., Leung, D., Bryden, L., Marlowe, L., Kaleem, M., Mastroeni, D., Grover, A., Rogers, J., Heun, R., Jessen, F., Kölsch, H., Heward, C.B., Ravid, R., Hutton, M.L., Melquist, S., Petersen, R.C., Caselli, R.J., Papassotiropoulos, A., Stephan, D.A., J., H., 2009. Whole genome association analysis shows that ACE is a risk factor for Alzheimer's disease and fails to replicate most candidates from Meta-analysis. *Int J Mol Epidemiol Genet* 1, 19–30.
- Webster, S., Glabe, C., Rogers, J., 1995. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. *Biochem Biophys Res Commun* 217, 869–875.
- Webster, S., Lue, L.F., Brachova, L., Tenner, A.J., McGeer, P.L., Terai, K., Walker, D.G., Bradt, B., Cooper, N.R., Rogers, J., 1997. Molecular and cellular characterization of the membrane attack complex. *Alzheimer's Dis Neurobiol Aging* 18, 415–421.
- Weisgraber, K.H., 1994. Apolipoprotein E: structure-function relationships. *Adv Protein Chem* 45249–45302.
- Whitmer, R.A., Gunderson, E.P., Quesenberry, C.P., Jr, Zhou, J., Yaffe, K., 2007. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. *Curr Alzheimer Res* 4, 103–109.
- Whitmer, R.A., Gustafson, D.R., Barrett-Connor, E., Haan, M.N., Gunderson, E.P., Yaffe, K., 2008. Central obesity and increased risk of dementia more than three decades later. *Neurology* 71, 1057–1064.
- Whitmer, R.A., Sidney, S., Selby, J., Johnston, S.C., Yaffe, K., 2005. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* 64, 277–281.
- Wilson, M.R., Easterbrook-Smith, S.B., 2000. Clusterin is a secreted mammalian chaperone. *Trends Biochem Sci* 25, 95–98.
- Wong, P., Pineault, J., Lakins, J., Taillefer, D., Leger, J., Wang, C., Tenniswood, M., 1993. Genomic organization and expression of the rat TRPM-two (clusterin) gene, a gene implicated in apoptosis. *J Biol Chem* 268, 5021–5031.
- Woods, C.G., Valente, E.M., Bond, J., Roberts, E., 2004. A new method for autozygosity mapping using single nucleotide polymorphisms (SNPs) and EXCLUDEAR. *J Med Genet* 41, e101.
- Yoshikai, S., Sasaki, H., Doh-Ura, K., Furuya, H., Sakaki, Y., 1990. Genomic organization of the human amyloid beta-protein precursor gene. *Gene* 87, 257–263.
- Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiya, K., Kawano, H., Ueda, K., 1995. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. *Neurology* 45, 1161–1168.
- Zannis, V.I., Just, P.W., Breslow, J.L., 1981. Human apolipoprotein E isoprotein subclasses are genetically determined. *Am J Hum Genet* 33, 11–24.
- Zipfel, P.F., 2009. Complement and Immune Defense: From Innate Immunity to Human Diseases. *Immunol Lett* 126, 1–7.
- Zlokovic, B.V., 1996. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood–brain barrier. *Life Sci* 59, 1483–1497.